1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Parkinson Disease, Secondary in 799 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest tremor in the limbs." | 7.68 | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism." | 7.68 | Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys. ( Kuno, S; Mizuta, E; Nishida, J; Takechi, M, 1992) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 7.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Building upon our expertise in Parkinson's disease translational research, the present study addressed this gap comparing plasma and cerebrospinal fluid bioavailability of l-3,4-dihydroxyphenylalanine, carbamazepine, quinidine, lovastatin, and simvastatin, in healthy and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques, the gold standard model of Parkinson's disease." | 5.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| "Treatment with paroxetine prevented degeneration of nigrostriatal DA neurons, increased striatal dopamine levels, and improved motor function." | 5.36 | Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. ( Chung, YC; Jin, BK; Kim, SR, 2010) |
| " All animals underwent the same behavioral and pharmacologic magnetic resonance imaging (phMRI) procedures to measure changes in basal ganglia function in response to dopaminergic drug challenges consisting of apomorphine administration followed by either a D1 (SCH23390) or a D2 (raclopride) receptor antagonist." | 3.81 | Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function. ( Andersen, AH; Forman, E; Gash, DM; Gerhardt, GA; Grondin, RC; Hardy, PA; Zhang, Z, 2015) |
| " Three African green monkeys were systemically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) until parkinsonian signs, including akinesia, rigidity, and a prominent 4- to 8-Hz tremor, appeared." | 3.69 | The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. ( Bergman, H; DeLong, MR; Karmon, B; Wichmann, T, 1994) |
| "Transient exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome resembling idiopathic parkinsonism (IP)." | 3.69 | Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. ( Calne, DB; Langston, JW; Schulzer, M; Snow, BJ; Tetrud, JW; Vingerhoets, FJ, 1994) |
| " Polymer-encapsulated PC12 cells, a dopaminergic cell line derived from a rat pheochromocytoma, were transplanted in five Macaca fascicularis monkeys which had been previously rendered hemiparkinsonian by a unilateral carotid injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 3.69 | Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. ( Aebischer, P; Goddard, M; Signore, AP; Timpson, RL, 1994) |
| "The antitremor effect of the D2 agonist LY 171555 and of the D1 agonist CY 208-243 alone and in combination was tested in a monkey previously rendered parkinsonian by MPTP and displaying exceptionally a rest tremor in the limbs." | 3.68 | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1992) |
| "The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism." | 3.68 | Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys. ( Kuno, S; Mizuta, E; Nishida, J; Takechi, M, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "We assessed clinical and electrophysiologic characteristics of tremor in patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.68 | Tremor in MPTP-induced parkinsonism. ( Langston, JW; Tetrud, JW, 1992) |
| "The purported alpha 2-adrenergic agonist clonidine was found to inhibit rest tremor at doses of 0." | 3.68 | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B, 1991) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Animal models of Parkinson's disease (PD) have been widely used in the past four decades to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder." | 2.48 | Animal models of Parkinson's disease. ( Armentero, MT; Blandini, F, 2012) |
| " We further found that oral CoQ10 was well absorbed in parkinsonian patients and caused a trend toward increased complex I activity." | 2.40 | A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. ( Beal, MF; Haas, RH; Shults, CW, 1999) |
| "The biochemical process underlying Parkinson's disease is dopamine cell death of the nigrostriatal system." | 2.38 | Type B monoamine oxidase and neurotoxins. ( Maruyama, W; Naoi, M, 1993) |
| " Regular dosing with levodopa or apomorphine reliably resulted in peak dose dyskinesia." | 2.38 | The use of thalamotomy in the treatment of levodopa-induced dyskinesia. ( Page, RD, 1992) |
| "Since the original description of Parkinson's disease (PD) more than 170 years ago, there have been major advances in the understanding and treatment of PD." | 2.38 | Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? ( Poirier, J; Thiffault, C, 1993) |
| "Selegiline (L-deprenyl) has been shown to delay the need to initiate levodopa therapy in early PD, and selegiline has also been suggested to increase the survival of PD patients." | 2.38 | Nigral degeneration in Parkinson's disease. ( Rinne, JO, 1993) |
| "Selegiline treatment increased the number of motoneurons surviving axotomy from 24 to 52%, showing that selegiline can rescue neurons by partially compensating for the loss of target-derived trophic support." | 2.38 | Selegiline can mediate neuronal rescue rather than neuronal protection. ( Tatton, WG, 1993) |
| "The cause of dopamine cell death in Parkinson's disease remains unknown." | 2.38 | Oxidative stress as a cause of Parkinson's disease. ( Jenner, P, 1991) |
| " Mechanisms of bioactivation by MAO-B of MPTP to MPP+, concentration of MPP+ in neurons with a catecholamine uptake system, and vulnerability to cellular toxic effects of MPP+ are the basis for the specificity of MPTP targeting of nigrostriatal dopaminergic neurons." | 2.37 | MPTP toxicity: implications for research in Parkinson's disease. ( Kopin, IJ; Markey, SP, 1988) |
| " Chronic administration of CP690550 (3 and 10 mg/kg, po) for 7 days significantly reversed the behavioural, biochemical and histological alterations induced by MPTP." | 1.72 | Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice. ( Albekairi, NA; Albekairi, TH; Alharbi, M; Alharbi, OO; Alshammari, A; Singh, S; Yeapuri, P, 2022) |
| "Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice." | 1.62 | Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. ( Cui, C; Hong, H; Huang, SB; Jia, XB; Qiao, CM; Shen, YQ; Shi, Y; Wu, J; Yao, L; Zhao, WJ; Zhou, Y, 2021) |
| " Mice were put on the subacute dosing regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral degeneration of the nigrostriatal pathway consistent with early-stage PD." | 1.51 | Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model. ( Jackson-Lewis, V; Ji, R; Karakatsani, ME; Konofagou, EE; Murillo, MF; Niimi, Y; Przedborski, S; Smith, M, 2019) |
| "More than 90% of the cases of Parkinson's disease have unknown etiology." | 1.48 | Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. ( Amiry-Moghaddam, M; Berg, T; Leergaard, TB; MacAulay, N; Mylonakou, MN; Ottersen, OP; Paulsen, RE; Prydz, A; Rahmani, S; Skare, Ø; Skauli, N; Stahl, K; Torp, R, 2018) |
| "Circuitry models of Parkinson's disease (PD) are based on striatal dopamine loss and aberrant striatal inputs into the basal ganglia network." | 1.43 | Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease. ( DeLong, MR; Gross, RE; Mewes, K; Obeso, JA; Papa, SM; Singh, A, 2016) |
| "Building upon our expertise in Parkinson's disease translational research, the present study addressed this gap comparing plasma and cerebrospinal fluid bioavailability of l-3,4-dihydroxyphenylalanine, carbamazepine, quinidine, lovastatin, and simvastatin, in healthy and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques, the gold standard model of Parkinson's disease." | 1.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| " Recently, SAC has also been shown to induce neuroprotection in the rat striatum in a toxic model induced by 6-hydroxydopamine in rats through a concerted antioxidant response involving Nrf2 transcription factor nuclear transactivation and Phase 2 enzymes' upregulation." | 1.40 | S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2. ( Colín-González, AL; Galván-Arzate, S; García, E; Heras, Y; Maldonado, PD; Santamaría, A; Santana-Martínez, R; Silva-Islas, CA; Sotelo, J, 2014) |
| "Pretreatment with hemantane (10 mg/kg) and the reference drug amantadine (20 mg/kg) 5 days before MPTP and further administration during 3 weeks after MPTP preserve cognitive function and prevented depressive disturbances in rats." | 1.38 | [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease]. ( Ivanova, EA; Kapitsa, IG; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2012) |
| " Chronic administration of MPTP induces lesion via apoptosis." | 1.38 | Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. ( Arun, A; Donmez, G; Ellis, L; Liu, L; Peritore, C, 2012) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "The development of Parkinson's disease is accompanied by concurrent activation of caspase-3 and apoptosis of dopaminergic neurons of human patients and rodent models." | 1.36 | Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. ( Amutuhaire, W; Ichinose, F; Kaneki, M; Kida, K; Yamada, M, 2010) |
| "The tremor is intermittent and does not appear in all human patients." | 1.36 | Computational physiology of the basal ganglia in Parkinson's disease. ( Bergman, H; Elias, S; Heimer, G; Rivlin-Etzion, M, 2010) |
| "Treatment with paroxetine prevented degeneration of nigrostriatal DA neurons, increased striatal dopamine levels, and improved motor function." | 1.36 | Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. ( Chung, YC; Jin, BK; Kim, SR, 2010) |
| "Depression is a frequently encountered non-motor feature of Parkinson's disease (PD) and it can have a significant impact on patient's quality of life." | 1.36 | Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. ( Andreatini, R; Barbieiro, J; Dombrowski, PA; Lima, MM; Santiago, RM; Vital, MA, 2010) |
| " 30 C57BL/6J mice were randomly divided into six groups: control group, PD model group, QXT high dosage group, QXT middle dosage group, QXT low dosage group and trihexyphenidyl hydrochloride group." | 1.35 | [Effection of Qing-Xuan tablets on behavior pattern and striatal TNF-alpha of Parkinson model mice]. ( Huo, QL; Lin, XX; Liu, MN; Liu, SJ; Yang, L; Yang, XX, 2009) |
| " In the present study, we found MPTP chronic administration significantly induced motor coordination impairment in mice." | 1.35 | Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. ( Chen, BY; Chiou, RY; Hsieh, CW; Huang, JC; Ko, MC; Lee, MC; Lu, KT; Peng, CH; Wung, BS; Yang, YL, 2008) |
| "Pre-treatment with captopril induced a significant reduction in the MPTP-induced loss of dopaminergic neurons in the substantia nigra and a significant reduction in the loss of dopaminergic terminals in the striatum." | 1.33 | Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. ( Guerra, MJ; Labandeira-Garcia, JL; Mendez-Alvarez, E; Muñoz, A; Rey, P; Soto-Otero, R, 2006) |
| " All betaCs and MPP(+) showed general cytotoxicity in parental HEK-293 cells after 72 h with half-maximal toxic concentrations (TC(50) values) in the upper micromolar range." | 1.32 | Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. ( Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A, 2004) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| "Although the cause of Parkinson's disease (PD) is unknown, data suggest roles for environmental factors that may sensitize dopaminergic neurons to age-related dysfunction and death." | 1.31 | Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. ( Cadet, JL; Cutler, RG; Duan, W; Kruman, II; Ladenheim, B; Mattson, MP, 2002) |
| "Murine model of Parkinson's disease uses a quite selective toxic effect of MPTP on nigrostriatal system." | 1.31 | [Treatment of neurodegenerative diseases: new perspectives]. ( Członkowska, A; Kurkowska-Jastrzebska, I, 2001) |
| "Pretreatment with ginsenoside Rg1 was shown to prevent the loss of Nissl staining neurons and TH-positive neurons, and decrease the percent of TUNEL-positive." | 1.31 | [Possible mechanisms of the protective effect of ginsenoside Rg1 on apoptosis in substantia nigra neurons]. ( Chen, XC; Chen, Y, 2002) |
| "In animal models of Parkinson's disease, loss of striatal dopamine leads to enhanced excitation of striatal NR2B-containing NMDA receptors." | 1.31 | Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D, 2000) |
| "Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo." | 1.31 | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000) |
| " Selective adenosine A(2A) receptor antagonists, such as KW-6002, may be one means of reducing the dosage of L-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs." | 1.31 | Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. ( Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA, 2000) |
| " These results indicate that the mode of administration of a D2 dopamine receptor agonist, such as U91356A, although at a roughly equivalent dosage influences the extent of inhibition of the expression of PPE in the denervated striatum of monkeys." | 1.30 | Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. ( Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Morissette, M; Soghomonian, JJ, 1997) |
| " High dosage nicotine treatment significantly increased the MPTP-induced loss of body weight and resulted in a significantly decreased striatal dopamine content and an increased dopamine turnover in comparison with the MPTP-treated controls at day 15." | 1.30 | Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. ( Earl, CD; Ferger, B; Kuschinsky, K; Oertel, WH; Spratt, C; Teismann, P, 1998) |
| "Lisuride was applied to 4 x 5 cm of skin of the abdomen of monkeys." | 1.30 | [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease]. ( Fukuda, T; Irifune, M; Iwata, S; Kaseda, S; Nomoto, M; Osame, M, 1998) |
| " We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0." | 1.30 | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. ( Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K, 1997) |
| " Adverse responses to Sinemet treatment alone in parkinsonian animals included vomiting, dykinesias, dystonias, and stereotypic movements." | 1.30 | Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. ( Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z, 1997) |
| "Therapeutic treatment of parkinsonian monkeys by chronic administration of levodopa (l-DOPA) leads to the development of dyskinesias and other motor fluctuations." | 1.30 | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. ( Frohna, PA; Joyce, JN; Rioux, L; Schneider, JS, 1997) |
| "The pathophysiology of dystonia is unclear, but several clues implicate striatal dopamine dysfunction." | 1.30 | MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia. ( Black, KJ; Parkinson, D; Perlmutter, JS; Tempel, LW; Todd, RD, 1997) |
| "The effects of a single treatment or chronic administration of cabergoline (1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)p ropyl]-3-ethyl-urea), a potent, long-lasting dopamine receptor agonist, on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in common marmosets were studied." | 1.30 | Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets. ( Fukuda, T; Iwata, SI; Kaseda, S; Kita, S; Nomoto, M, 1998) |
| "Parkinson's disease is characterized by degeneration of dopamine (DA) neurons and their terminals." | 1.30 | SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys. ( Babich, JW; Barrow, SA; Elmaleh, DR; Fischman, AJ; Hanson, RN; Madras, BK; Meltzer, P, 1997) |
| " When combined with N-0923, nicotine did not further enhance its effects." | 1.30 | Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys. ( Domino, EF; Ni, L; Zhang, H, 1999) |
| "Nicotine is a natural alkaloid that has considerable stimulatory effects on the central nervous system (CNS)." | 1.30 | Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. ( Corsini, GU; Fornai, F; Maggio, R; Racagni, G; Riva, M; Vaglini, F, 1997) |
| "Pretreatment with nimodipine (120 mg pellets) did neither attenuate the behavioural impairments in MPTP-treated animals nor antagonize the striatal neurotoxin-induced dopamine depletion, but almost completely prevented (in a dose-dependent manner) the MPTP-induced decrease of nigral tyrosine hydroxylase immunoreactive cells." | 1.29 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. ( Gerlach, M; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J, 1996) |
| "Riluzole was administered twice 15 min before, and 24 h after, the lesion." | 1.29 | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. ( Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S, 1996) |
| " Twelve adult female Japanese monkeys weighing about 7kg were lesioned with systemic infusion of MPTP according to the following dosing schedules." | 1.29 | [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model]. ( Takeda, M, 1995) |
| "Remacemide hydrochloride is an anticonvulsant, neuroprotective compound with antagonist activity at the N-methyl-D-aspartate receptor ion channel." | 1.29 | Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. ( Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z, 1994) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "We examined whether or not the antiparkinsonian activity of talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine) could be optimised by combination with L-3,4-dihydroxyphenylalanine (L-dopa)." | 1.29 | Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment. ( Fukuda, T; Irifune, M; Nomoto, M, 1994) |
| "Apomorphine treatment was found to result in higher rates of glucose utilization in the denervated striatum than in the intact hemisphere." | 1.29 | Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. ( Pontieri, FE; Porrino, LJ; Sokoloff, L; Viola, JJ, 1995) |
| " Using a MPTP dosing regimen a reversible parkinsonian-like syndrome was produced in the marmoset." | 1.28 | Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. ( Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS, 1990) |
| " We carried out an oral levodopa dose-response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP." | 1.28 | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. ( Gash, DM; Kim, MH; Kurlan, R, 1991) |
| "Haloperidol was found to have a similar metabolic pathway to that of the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice microsomal preparations." | 1.28 | Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. ( Fang, J; Gorrod, JW, 1991) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| " Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side." | 1.28 | [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. ( Chen, S, 1992) |
| " Chronic administration of L-deprenyl (0." | 1.28 | Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. ( Hashim, A; Lajtha, A; Sershen, H; Wiener, HL, 1989) |
| "Ropinirole did not cause marked stereotypies." | 1.28 | Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. ( Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991) |
| "Two patients with Parkinson's disease who underwent implantation of fetal mesencephalic tissue into the putamen were serially studied using positron emission tomography and [18F]6-L-fluorodopa ([18F]dopa)." | 1.28 | Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. ( Björklund, A; Bloomfield, PM; Brooks, DJ; Brundin, P; Leenders, KL; Lindvall, O; Marsden, CD; Rehncrona, S; Sawle, GV; Widner, H, 1992) |
| " The dose-response curve for NB-355 was shifted to the right such that approximately twice the dopa equivalent dose of NB-355 was required to stimulate locomotor activity to the same level observed for L-DOPA." | 1.28 | NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. ( Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ, 1989) |
| "Mazindol binding was decreased 30-98% in the caudate nucleus, 20-97% in the putamen, 0-26% in the nucleus accumbens, 80-96% in the substantia nigra pars compacta and 49-94% in the ventral tegmental area." | 1.28 | Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. ( Alexander, GM; Brainard, L; Gordon, SW; Grothusen, JR; Schwartzman, RJ, 1992) |
| "Although it is known that Parkinson's disease results from a loss of dopaminergic neurons in the substantia nigra, the resulting alterations in activity in the basal ganglia responsible for parkinsonian motor deficits are still poorly characterized." | 1.28 | Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. ( Bergman, H; DeLong, MR; Wichmann, T, 1990) |
| "Reactive gliosis was observed throughout the mouse striatum but not in the substantia nigra." | 1.27 | Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. ( Denaro, FJ; Schneider, JS, 1988) |
| "Idiopathic Parkinson's disease may derive from the action of an environmental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compound." | 1.27 | (-)Deprenyl in perspective: prophylaxis for Parkinson's disease? ( Sandler, M, 1986) |
| "To simulate an animal model of Parkinson's disease, MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) was administered to five monkeys." | 1.27 | Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. ( Imai, H; Itakura, T; Kamei, I; Komai, N; Naka, Y; Nakai, K; Nakakita, K, 1988) |
| " Some dissimilarities between both the conditions noticed in earlier investigations have been dissolved by starting a well-prescribed chronic administration of subliminal dose of MPTP in old matured monkeys." | 1.27 | Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism. ( Narabayashi, H, 1987) |
| " Rigidity and bradykinesia were induced by the chronic administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.27 | Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. ( Bakay, RA; Barrow, DL; Collins, DC; Fiandaca, MS; Schiff, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 207 (25.91) | 18.7374 |
| 1990's | 345 (43.18) | 18.2507 |
| 2000's | 141 (17.65) | 29.6817 |
| 2010's | 85 (10.64) | 24.3611 |
| 2020's | 21 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Zimmerman, DM | 1 |
| Cantrell, BE | 1 |
| Reel, JK | 1 |
| Hemrick-Luecke, SK | 1 |
| Fuller, RW | 1 |
| Zhang, J | 5 |
| Sun, B | 1 |
| Yang, J | 2 |
| Chen, Z | 2 |
| Li, Z | 3 |
| Zhang, N | 2 |
| Li, H | 1 |
| Shen, L | 1 |
| Huang, R | 1 |
| Gao, Y | 2 |
| Chen, J | 1 |
| Duan, Q | 1 |
| He, P | 1 |
| Huang, H | 1 |
| Zhang, Q | 1 |
| Ma, G | 1 |
| Zhang, Y | 5 |
| Nie, K | 1 |
| Wang, L | 2 |
| Alshammari, A | 1 |
| Alharbi, M | 1 |
| Albekairi, NA | 1 |
| Albekairi, TH | 1 |
| Alharbi, OO | 1 |
| Yeapuri, P | 1 |
| Singh, S | 1 |
| Hang, W | 1 |
| Fan, HJ | 1 |
| Li, YR | 1 |
| Xiao, Q | 1 |
| Jia, L | 1 |
| Song, LJ | 2 |
| Jin, XM | 1 |
| Xiao, BG | 2 |
| Yu, JZ | 1 |
| Ma, CG | 2 |
| Chai, Z | 1 |
| Leem, YH | 1 |
| Park, JS | 1 |
| Park, JE | 1 |
| Kim, DY | 1 |
| Kim, HS | 1 |
| Vora, U | 1 |
| Vyas, VK | 1 |
| Wal, P | 1 |
| Saxena, B | 1 |
| Song, J | 1 |
| Liu, L | 4 |
| Mao, T | 1 |
| Zhou, L | 2 |
| Chen, X | 1 |
| Shang, Y | 1 |
| Sun, T | 1 |
| Luo, Y | 1 |
| Jiang, Y | 2 |
| Tan, D | 1 |
| Tong, X | 1 |
| Dai, F | 1 |
| Wang, Y | 5 |
| Pu, Z | 4 |
| Du, Z | 3 |
| Guo, Z | 3 |
| Bai, Q | 4 |
| Kartik, S | 1 |
| Pal, R | 1 |
| Chaudhary, MJ | 1 |
| Tiwari, PC | 1 |
| Nath, R | 1 |
| Kumar, M | 1 |
| Huang, L | 1 |
| Ren, Y | 1 |
| Zeng, Z | 1 |
| Ren, H | 1 |
| Li, S | 2 |
| He, S | 1 |
| He, F | 1 |
| Li, X | 3 |
| Ji, R | 1 |
| Smith, M | 2 |
| Niimi, Y | 1 |
| Karakatsani, ME | 1 |
| Murillo, MF | 1 |
| Jackson-Lewis, V | 4 |
| Przedborski, S | 4 |
| Konofagou, EE | 1 |
| Hu, AL | 1 |
| Song, S | 1 |
| Li, Y | 6 |
| Xu, SF | 1 |
| Zhang, F | 1 |
| Li, C | 2 |
| Liu, J | 3 |
| Cui, X | 1 |
| Li, M | 2 |
| He, Z | 2 |
| Hu, L | 1 |
| Yan, J | 1 |
| Hua, L | 1 |
| Qiao, CM | 2 |
| Sun, MF | 1 |
| Jia, XB | 2 |
| Zhang, BP | 1 |
| Zhao, LP | 1 |
| Shi, Y | 2 |
| Zhou, ZL | 1 |
| Zhu, YL | 1 |
| Cui, C | 2 |
| Shen, YQ | 2 |
| Guo, YL | 1 |
| Duan, WJ | 1 |
| Lu, DH | 1 |
| Ma, XH | 1 |
| Li, XX | 1 |
| Bi, W | 1 |
| Kurihara, H | 1 |
| Liu, HZ | 1 |
| Li, YF | 1 |
| He, RR | 1 |
| Travagli, RA | 1 |
| Browning, KN | 1 |
| Camilleri, M | 1 |
| Jin, CF | 1 |
| Wang, ZZ | 1 |
| Chen, KZ | 1 |
| Xu, TF | 1 |
| Hao, GF | 1 |
| Liu, X | 1 |
| Liu, S | 2 |
| Tang, Y | 1 |
| Xiao, H | 1 |
| Gao, J | 1 |
| Yin, Q | 1 |
| Jia, Y | 1 |
| Zhou, Y | 1 |
| Wu, J | 1 |
| Hong, H | 1 |
| Huang, SB | 1 |
| Yao, L | 1 |
| Zhao, WJ | 2 |
| Wang, X | 2 |
| Liu, Z | 1 |
| Wang, F | 1 |
| Ning, XL | 1 |
| Li, YZ | 1 |
| Huo, C | 1 |
| Deng, J | 1 |
| Gao, C | 1 |
| Zhu, KR | 1 |
| Wang, M | 2 |
| Wu, YX | 1 |
| Yu, JL | 1 |
| Ren, YL | 1 |
| Luo, ZY | 1 |
| Li, G | 1 |
| Chen, Y | 7 |
| Wang, SY | 1 |
| Peng, C | 1 |
| Yang, LL | 1 |
| Wang, ZY | 1 |
| Wu, Y | 2 |
| Qian, S | 1 |
| Li, GB | 1 |
| Wada, M | 1 |
| Ang, MJ | 1 |
| Weerasinghe-Mudiyanselage, PDE | 1 |
| Kim, SH | 1 |
| Kim, JC | 1 |
| Shin, T | 1 |
| Moon, C | 1 |
| Özkan, A | 1 |
| Bülbül, M | 1 |
| Derin, N | 1 |
| Sinen, O | 1 |
| Akçay, G | 1 |
| Parlak, H | 1 |
| Aydın Aslan, M | 1 |
| Ağar, A | 2 |
| Go, S | 1 |
| Kurita, H | 1 |
| Yokoo, K | 1 |
| Inden, M | 1 |
| Kambe, T | 1 |
| Hozumi, I | 1 |
| López, A | 1 |
| Ortiz, F | 1 |
| Doerrier, C | 1 |
| Venegas, C | 1 |
| Fernández-Ortiz, M | 1 |
| Aranda, P | 1 |
| Díaz-Casado, ME | 1 |
| Fernández-Gil, B | 1 |
| Barriocanal-Casado, E | 1 |
| Escames, G | 1 |
| López, LC | 1 |
| Acuña-Castroviejo, D | 1 |
| Zhang, R | 1 |
| Andersen, AH | 5 |
| Hardy, PA | 2 |
| Forman, E | 3 |
| Evans, A | 1 |
| Ai, Y | 4 |
| Yue, J | 1 |
| Yue, G | 1 |
| Gash, DM | 15 |
| Grondin, R | 9 |
| Zhang, Z | 13 |
| Li, D | 2 |
| Yang, H | 1 |
| Ma, J | 2 |
| Luo, S | 1 |
| Chen, S | 7 |
| Gu, Q | 1 |
| Ge, G | 1 |
| Chen, C | 1 |
| Guderyon, MJ | 1 |
| Yu, Y | 1 |
| Clark, RA | 1 |
| Stahl, K | 1 |
| Rahmani, S | 1 |
| Prydz, A | 1 |
| Skauli, N | 1 |
| MacAulay, N | 1 |
| Mylonakou, MN | 1 |
| Torp, R | 1 |
| Skare, Ø | 1 |
| Berg, T | 1 |
| Leergaard, TB | 1 |
| Paulsen, RE | 1 |
| Ottersen, OP | 1 |
| Amiry-Moghaddam, M | 1 |
| Hu, XL | 1 |
| Lin, J | 1 |
| Lv, XY | 1 |
| Feng, JH | 1 |
| Zhang, XQ | 1 |
| Wang, H | 1 |
| Ye, WC | 1 |
| Abolaji, AO | 1 |
| Adedara, AO | 1 |
| Adie, MA | 1 |
| Vicente-Crespo, M | 1 |
| Farombi, EO | 1 |
| Yu, SJ | 1 |
| Lecca, D | 1 |
| Glotfelty, E | 1 |
| Kim, HK | 1 |
| Choi, HI | 1 |
| Hoffer, BJ | 3 |
| Greig, NH | 1 |
| Kim, DS | 3 |
| Choi, JG | 1 |
| Huh, E | 1 |
| Ju, IG | 1 |
| Kim, N | 1 |
| Yun, J | 1 |
| Oh, MS | 1 |
| Jia, M | 1 |
| Zhang, X | 1 |
| Wang, P | 1 |
| Sugumar, M | 1 |
| Sevanan, M | 1 |
| Sekar, S | 1 |
| Zhang, QS | 1 |
| Shao, QH | 2 |
| Wang, S | 2 |
| Yuan, YH | 2 |
| Chen, NH | 2 |
| Wang, HB | 1 |
| Ma, K | 1 |
| Han, C | 1 |
| Zhang, G | 1 |
| Guo, X | 1 |
| Xia, Y | 1 |
| Wan, F | 1 |
| Yin, S | 1 |
| Kou, L | 1 |
| Huang, J | 1 |
| Xiong, N | 1 |
| Wang, T | 1 |
| Li, FF | 1 |
| Zhang, XL | 1 |
| Al-Jarrah, M | 1 |
| Obaidat, H | 1 |
| Bataineh, Z | 1 |
| Walton, L | 1 |
| Al-Khateeb, A | 1 |
| Dixit, A | 1 |
| Srivastava, G | 1 |
| Verma, D | 1 |
| Mishra, M | 1 |
| Singh, PK | 1 |
| Prakash, O | 1 |
| Singh, MP | 1 |
| Ghosh, A | 1 |
| Saminathan, H | 1 |
| Kanthasamy, A | 2 |
| Anantharam, V | 1 |
| Jin, H | 1 |
| Sondarva, G | 1 |
| Harischandra, DS | 1 |
| Qian, Z | 1 |
| Rana, A | 1 |
| Kanthasamy, AG | 2 |
| Li, XZ | 1 |
| Zhang, SN | 1 |
| Lu, F | 1 |
| Liu, CF | 1 |
| Bai, Y | 1 |
| Wang, N | 1 |
| Liu, SM | 1 |
| Li, P | 1 |
| Zhang, ZJ | 1 |
| Ren, HB | 1 |
| Zhang, SZ | 1 |
| Wang, W | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| García, E | 1 |
| Santana-Martínez, R | 1 |
| Silva-Islas, CA | 1 |
| Colín-González, AL | 1 |
| Galván-Arzate, S | 1 |
| Heras, Y | 1 |
| Maldonado, PD | 1 |
| Sotelo, J | 1 |
| Santamaría, A | 1 |
| Kurtenbach, S | 1 |
| Wewering, S | 1 |
| Hatt, H | 1 |
| Neuhaus, EM | 1 |
| Lübbert, H | 1 |
| Yu, LH | 1 |
| Wei, HL | 1 |
| Bao, XQ | 2 |
| Zhang, D | 2 |
| Sun, H | 1 |
| Sohn, EJ | 2 |
| Shin, MJ | 2 |
| Kim, DW | 2 |
| Ahn, EH | 2 |
| Jo, HS | 1 |
| Cho, SW | 2 |
| Han, KH | 1 |
| Park, J | 2 |
| Eum, WS | 2 |
| Hwang, HS | 1 |
| Choi, SY | 2 |
| Nash, KR | 1 |
| Moran, P | 1 |
| Finneran, DJ | 1 |
| Hudson, C | 1 |
| Robinson, J | 1 |
| Morgan, D | 1 |
| Bickford, PC | 1 |
| Gerhardt, GA | 4 |
| Grondin, RC | 1 |
| Mathai, A | 1 |
| Ma, Y | 1 |
| Paré, JF | 1 |
| Villalba, RM | 2 |
| Wichmann, T | 8 |
| Smith, Y | 3 |
| Anitua, E | 1 |
| Pascual, C | 1 |
| Pérez-Gonzalez, R | 1 |
| Orive, G | 1 |
| Carro, E | 1 |
| Cappelletti, G | 1 |
| Casagrande, F | 1 |
| Calogero, A | 1 |
| De Gregorio, C | 1 |
| Pezzoli, G | 2 |
| Cartelli, D | 1 |
| Gao, L | 1 |
| Yang, RY | 1 |
| Lian, WW | 1 |
| Fang, JS | 1 |
| Pang, XC | 1 |
| Qin, XM | 1 |
| Liu, AL | 1 |
| Du, GH | 1 |
| da Rocha Lindner, G | 1 |
| Bonfanti Santos, D | 1 |
| Colle, D | 1 |
| Gasnhar Moreira, EL | 1 |
| Daniel Prediger, R | 1 |
| Farina, M | 1 |
| Khalil, NM | 1 |
| Mara Mainardes, R | 1 |
| Jiang, W | 1 |
| Wang, Z | 1 |
| Lu, M | 1 |
| Hong, J | 1 |
| Sha, S | 1 |
| Wang, C | 1 |
| Yin, J | 1 |
| Chen, L | 2 |
| Khakimova, GR | 1 |
| Kozina, EA | 2 |
| Buneeva, OA | 1 |
| Aksenova, LN | 1 |
| Medvedev, AE | 1 |
| Ugryumov, MV | 1 |
| Franke, SK | 1 |
| van Kesteren, RE | 1 |
| Wubben, JA | 1 |
| Hofman, S | 1 |
| Paliukhovich, I | 1 |
| van der Schors, RC | 1 |
| van Nierop, P | 1 |
| Smit, AB | 1 |
| Philippens, IH | 1 |
| Wu, R | 1 |
| Chen, H | 1 |
| He, Q | 1 |
| Huang, Q | 1 |
| Liu, Q | 1 |
| Yuan, Z | 1 |
| Thiollier, T | 1 |
| Wu, C | 1 |
| Contamin, H | 1 |
| Li, Q | 3 |
| Bezard, E | 12 |
| Zhao, XD | 2 |
| Wang, FX | 1 |
| Cao, WF | 1 |
| Zhang, YH | 1 |
| Al-Sweidi, S | 1 |
| Morissette, M | 5 |
| Di Paolo, T | 13 |
| Cheng, L | 1 |
| Quek, CY | 1 |
| Hung, LW | 1 |
| Sharples, RA | 1 |
| Sherratt, NA | 1 |
| Barnham, KJ | 1 |
| Hill, AF | 1 |
| Sarath Babu, N | 1 |
| Murthy, ChL | 1 |
| Kakara, S | 1 |
| Sharma, R | 1 |
| Brahmendra Swamy, CV | 1 |
| Idris, MM | 1 |
| Hopes, L | 1 |
| Grolez, G | 1 |
| Moreau, C | 1 |
| Lopes, R | 1 |
| Ryckewaert, G | 1 |
| Carrière, N | 1 |
| Auger, F | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Devedjian, JC | 1 |
| Bordet, R | 1 |
| Defebvre, L | 1 |
| Jissendi, P | 1 |
| Delmaire, C | 1 |
| Devos, D | 1 |
| Morin, N | 1 |
| Grégoire, L | 5 |
| Rajput, A | 1 |
| Rajput, AH | 1 |
| Xing, LF | 1 |
| Guo, HP | 1 |
| Wang, DT | 1 |
| Sun, LH | 1 |
| Pan, SY | 1 |
| Lin, CY | 1 |
| Hsieh, HY | 1 |
| Chen, CM | 1 |
| Wu, SR | 1 |
| Tsai, CH | 1 |
| Huang, CY | 1 |
| Hua, MY | 1 |
| Wei, KC | 1 |
| Yeh, CK | 1 |
| Liu, HL | 1 |
| Jiang, X | 1 |
| Zhai, S | 1 |
| Xing, D | 1 |
| Guo, YJ | 1 |
| Dong, SY | 1 |
| Cui, XX | 1 |
| Feng, Y | 1 |
| Liu, T | 1 |
| Yin, M | 1 |
| Kuo, SH | 1 |
| Tan, EK | 1 |
| Wu, YC | 1 |
| Singh, A | 3 |
| Verma, P | 1 |
| Balaji, G | 1 |
| Samantaray, S | 2 |
| Mohanakumar, KP | 1 |
| Mewes, K | 2 |
| Gross, RE | 1 |
| DeLong, MR | 9 |
| Obeso, JA | 10 |
| Papa, SM | 2 |
| Chung, YC | 3 |
| Shin, WH | 1 |
| Baek, JY | 1 |
| Cho, EJ | 1 |
| Baik, HH | 1 |
| Kim, SR | 2 |
| Won, SY | 1 |
| Jin, BK | 4 |
| Li, YH | 1 |
| Yu, JW | 1 |
| Xi, JY | 1 |
| Yu, WB | 1 |
| Liu, JC | 1 |
| Wang, Q | 3 |
| Feng, L | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Wang, YD | 2 |
| Xu, S | 1 |
| Yu, WW | 1 |
| Cao, SN | 1 |
| Hu, JP | 1 |
| Wang, XL | 1 |
| Yu, SS | 1 |
| Li, DW | 1 |
| Zhou, SY | 1 |
| Sun, WP | 1 |
| Lee, JH | 1 |
| Bok, E | 1 |
| Lee, H | 1 |
| Huh, SH | 1 |
| Lee, JE | 1 |
| Ko, HW | 1 |
| Belloli, S | 1 |
| Pannese, M | 1 |
| Buonsanti, C | 1 |
| Maiorino, C | 1 |
| Di Grigoli, G | 1 |
| Carpinelli, A | 1 |
| Monterisi, C | 1 |
| Moresco, RM | 1 |
| Panina-Bordignon, P | 1 |
| Weng, CC | 1 |
| Chen, ZA | 1 |
| Chao, KT | 1 |
| Ee, TW | 1 |
| Lin, KJ | 1 |
| Chan, MH | 1 |
| Hsiao, IT | 1 |
| Yen, TC | 1 |
| Kung, MP | 1 |
| Hsu, CH | 1 |
| Wey, SP | 1 |
| Ding, F | 2 |
| Walton, AA | 1 |
| Surgener, SP | 1 |
| Emborg, ME | 3 |
| Ebert, AD | 1 |
| Moirano, J | 1 |
| Peng, S | 1 |
| Suzuki, M | 1 |
| Capowski, E | 1 |
| Joers, V | 1 |
| Roitberg, BZ | 1 |
| Aebischer, P | 3 |
| Svendsen, CN | 1 |
| Luan, L | 1 |
| Andersen, A | 1 |
| Hardy, P | 1 |
| Lu, KT | 1 |
| Ko, MC | 1 |
| Chen, BY | 1 |
| Huang, JC | 1 |
| Hsieh, CW | 1 |
| Lee, MC | 1 |
| Chiou, RY | 1 |
| Wung, BS | 1 |
| Peng, CH | 1 |
| Yang, YL | 1 |
| Liu, B | 4 |
| Shi, Q | 1 |
| Ma, S | 1 |
| Feng, N | 1 |
| Li, J | 1 |
| Pretorius, A | 1 |
| Ogunrombi, MO | 1 |
| Terre'blanche, G | 1 |
| Castagnoli, N | 5 |
| Bergh, JJ | 1 |
| Petzer, JP | 3 |
| Zheng, H | 2 |
| Zhang, ZF | 2 |
| Zhang, YX | 2 |
| Natale, G | 1 |
| Kastsiuchenka, O | 1 |
| Pasquali, L | 1 |
| Ruggieri, S | 2 |
| Paparelli, A | 2 |
| Fornai, F | 5 |
| Shi, C | 1 |
| Kim, NK | 1 |
| Choi, BH | 1 |
| Huang, X | 1 |
| Snyder, BJ | 1 |
| Bukhari, S | 1 |
| Kong, TH | 1 |
| Park, H | 1 |
| Park, HC | 1 |
| Park, SR | 1 |
| Ha, Y | 1 |
| Rubio-Osornio, M | 1 |
| Montes, S | 1 |
| Pérez-Severiano, F | 1 |
| Aguilera, P | 1 |
| Floriano-Sánchez, E | 1 |
| Monroy-Noyola, A | 1 |
| Rubio, C | 1 |
| Ríos, C | 3 |
| Price, DA | 1 |
| Martinez, AA | 1 |
| Seillier, A | 1 |
| Koek, W | 1 |
| Acosta, Y | 1 |
| Fernandez, E | 1 |
| Strong, R | 1 |
| Lutz, B | 1 |
| Marsicano, G | 1 |
| Roberts, JL | 1 |
| Giuffrida, A | 1 |
| Prediger, RD | 1 |
| Aguiar, AS | 1 |
| Rojas-Mayorquin, AE | 1 |
| Figueiredo, CP | 1 |
| Matheus, FC | 1 |
| Ginestet, L | 1 |
| Chevarin, C | 1 |
| Bel, ED | 1 |
| Mongeau, R | 1 |
| Hamon, M | 1 |
| Lanfumey, L | 1 |
| Raisman-Vozari, R | 1 |
| De Pablos, V | 1 |
| Barcia, C | 1 |
| Martínez, S | 1 |
| Gomez, A | 1 |
| Ros-Bernal, F | 1 |
| Zamarro-Parra, J | 1 |
| Soria-Torrecillas, JJ | 1 |
| Hernández, J | 1 |
| Ceron, JJ | 1 |
| Herrero, MT | 10 |
| Su, X | 1 |
| Kells, AP | 1 |
| Huang, EJ | 1 |
| Lee, HS | 1 |
| Hadaczek, P | 1 |
| Beyer, J | 1 |
| Bringas, J | 4 |
| Pivirotto, P | 6 |
| Penticuff, J | 1 |
| Eberling, J | 1 |
| Federoff, HJ | 5 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 18 |
| VanLeeuwen, JE | 1 |
| Petzinger, GM | 3 |
| Walsh, JP | 2 |
| Akopian, GK | 1 |
| Vuckovic, M | 1 |
| Jakowec, MW | 3 |
| Raju, DV | 1 |
| Zigmond, MJ | 1 |
| Cameron, JL | 2 |
| Leak, RK | 2 |
| Mirnics, K | 2 |
| Russell, VA | 1 |
| Smeyne, RJ | 4 |
| Smith, AD | 1 |
| Yang, XX | 1 |
| Yang, L | 3 |
| Huo, QL | 1 |
| Liu, MN | 1 |
| Lin, XX | 1 |
| Liu, SJ | 1 |
| Xu, K | 1 |
| Xu, YH | 1 |
| Chen, JF | 3 |
| Schwarzschild, MA | 4 |
| Santiago, RM | 1 |
| Barbieiro, J | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Andreatini, R | 1 |
| Vital, MA | 1 |
| Khaindrava, VG | 1 |
| Kucherianu, VG | 8 |
| Kryzhanovskiĭ, GN | 9 |
| Kudrin, VS | 3 |
| Klodt, PD | 1 |
| Bocharov, EV | 1 |
| Raevskiĭ, KS | 1 |
| Ugriumov, MV | 1 |
| Rivlin-Etzion, M | 1 |
| Elias, S | 1 |
| Heimer, G | 1 |
| Bergman, H | 11 |
| Fredriksson, A | 3 |
| Stigsdotter, IM | 1 |
| Hurtig, A | 1 |
| Ewalds-Kvist, B | 1 |
| Archer, T | 3 |
| Yamada, M | 1 |
| Kida, K | 1 |
| Amutuhaire, W | 1 |
| Ichinose, F | 1 |
| Kaneki, M | 1 |
| Vučković, MG | 1 |
| Fisher, B | 1 |
| Nacca, A | 1 |
| Leahy, RM | 1 |
| Mukherjee, J | 1 |
| Williams, C | 1 |
| Tanriover, G | 1 |
| Seval-Celik, Y | 1 |
| Ozsoy, O | 1 |
| Akkoyunlu, G | 1 |
| Savcioglu, F | 1 |
| Hacioglu, G | 1 |
| Demir, N | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 4 |
| Subramanian, T | 1 |
| Fernagut, PO | 2 |
| Dovero, S | 3 |
| Chan, P | 1 |
| Wu, T | 1 |
| Ravenscroft, P | 2 |
| Hill, M | 1 |
| Yin, SM | 1 |
| Yu, DQ | 1 |
| An, N | 1 |
| Li, YB | 1 |
| Wang, SL | 1 |
| Zimin, IA | 1 |
| Kapitsa, IG | 2 |
| Voronina, TA | 4 |
| Kovalev, GI | 2 |
| Lira, A | 1 |
| Kulczycki, J | 1 |
| Slack, R | 1 |
| Anisman, H | 1 |
| Park, DS | 1 |
| Salimov, RM | 1 |
| King, JM | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| Charlton, C | 1 |
| Mudò, G | 1 |
| Mäkelä, J | 1 |
| Di Liberto, V | 1 |
| Tselykh, TV | 1 |
| Olivieri, M | 1 |
| Piepponen, P | 1 |
| Eriksson, O | 1 |
| Mälkiä, A | 1 |
| Bonomo, A | 1 |
| Kairisalo, M | 1 |
| Aguirre, JA | 1 |
| Korhonen, L | 1 |
| Belluardo, N | 1 |
| Lindholm, D | 1 |
| Bové, J | 2 |
| Perier, C | 2 |
| Blandini, F | 1 |
| Armentero, MT | 1 |
| Lee, YP | 1 |
| Kang, HW | 1 |
| Hwang, JH | 1 |
| Jeong, HJ | 1 |
| Kim, MJ | 1 |
| Kang, TC | 1 |
| Kwon, OS | 1 |
| Arun, A | 1 |
| Ellis, L | 1 |
| Peritore, C | 1 |
| Donmez, G | 1 |
| Fanara, P | 1 |
| Wong, PY | 1 |
| Husted, KH | 1 |
| Liu, VM | 1 |
| Kohlstaedt, LA | 1 |
| Riiff, T | 1 |
| Protasio, JC | 1 |
| Boban, D | 1 |
| Killion, S | 1 |
| Killian, M | 1 |
| Epling, L | 1 |
| Sinclair, E | 1 |
| Peterson, J | 1 |
| Price, RW | 1 |
| Cabin, DE | 1 |
| Nussbaum, RL | 1 |
| Brühmann, J | 1 |
| Brandt, R | 1 |
| Christine, CW | 1 |
| Aminoff, MJ | 1 |
| Hellerstein, MK | 1 |
| Garbett, KA | 1 |
| Dettmer, AM | 1 |
| Lee, J | 1 |
| Parsons, D | 1 |
| Janaurajs, K | 1 |
| Standaert, DG | 1 |
| Nepoklonov, AV | 1 |
| Ivanova, EA | 1 |
| Val'dman, EA | 1 |
| Hamilton, GS | 3 |
| Wu, YQ | 3 |
| Limburg, DC | 2 |
| Wilkinson, DE | 2 |
| Vaal, MJ | 1 |
| Li, JH | 3 |
| Thomas, C | 1 |
| Huang, W | 1 |
| Sauer, H | 2 |
| Ross, DT | 1 |
| Soni, R | 2 |
| Guo, H | 3 |
| Howorth, P | 2 |
| Valentine, H | 2 |
| Liang, S | 2 |
| Spicer, D | 3 |
| Fuller, M | 3 |
| Steiner, JP | 3 |
| Limburg, D | 1 |
| Ross, D | 1 |
| Suganuma, H | 1 |
| Hirano, T | 1 |
| Arimoto, Y | 1 |
| Inakuma, T | 1 |
| Klintenberg, R | 1 |
| Svenningsson, P | 1 |
| Gunne, L | 1 |
| Andrén, PE | 2 |
| Vieregge, P | 1 |
| Choi, JY | 1 |
| Park, CS | 1 |
| Kim, DJ | 1 |
| Cho, MH | 1 |
| Pie, JE | 1 |
| Chung, WG | 1 |
| Kulak, JM | 2 |
| Musachio, JL | 1 |
| McIntosh, JM | 2 |
| Quik, M | 6 |
| Di Monte, DA | 4 |
| Lavasani, M | 1 |
| Manning-Bog, AB | 1 |
| Mandel, S | 4 |
| Grünblatt, E | 3 |
| Maor, G | 3 |
| Youdim, MB | 9 |
| Chen, XC | 1 |
| Steyn, S | 1 |
| Castagnoli, KP | 1 |
| Van der Schyf, CJ | 1 |
| Robinson, S | 1 |
| Freeman, P | 1 |
| Moore, C | 1 |
| Touchon, JC | 1 |
| Krentz, L | 1 |
| Meshul, CK | 1 |
| Kaur, D | 1 |
| Yantiri, F | 2 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 2 |
| Viswanath, V | 2 |
| Jacobs, R | 1 |
| Beal, MF | 5 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 3 |
| Bélanger, N | 1 |
| Bédard, P | 3 |
| Prunier, C | 2 |
| Montharu, J | 1 |
| Mantzarides, M | 1 |
| Besnard, JC | 1 |
| Baulieu, JL | 1 |
| Gross, C | 8 |
| Guilloteau, D | 3 |
| Chalon, S | 3 |
| Gao, HM | 2 |
| Zhang, W | 3 |
| Hong, JS | 2 |
| He, Y | 1 |
| Thong, PS | 1 |
| Lee, T | 1 |
| Leong, SK | 1 |
| Mao, BY | 1 |
| Dong, F | 1 |
| Watt, F | 1 |
| Oiwa, Y | 1 |
| Eberling, JL | 5 |
| Nagy, D | 2 |
| Thomas, BE | 1 |
| Feng, Z | 1 |
| Fung, PC | 1 |
| Pei, Z | 1 |
| Ramsden, DB | 3 |
| Ho, SL | 1 |
| Schneider, JS | 31 |
| Gonczi, H | 1 |
| Decamp, E | 1 |
| Brownell, AL | 5 |
| Canales, K | 1 |
| Chen, YI | 1 |
| Jenkins, BG | 2 |
| Owen, C | 1 |
| Livni, E | 1 |
| Yu, M | 1 |
| Cicchetti, F | 1 |
| Sanchez-Pernaute, R | 1 |
| Isacson, O | 5 |
| Samadi, P | 1 |
| Bédard, PJ | 23 |
| Schröder, N | 1 |
| Bibbiani, F | 2 |
| Oh, JD | 2 |
| Chase, TN | 6 |
| Van Kampen, J | 1 |
| Robertson, H | 1 |
| Hagg, T | 1 |
| Drobitch, R | 1 |
| Lutsenko, VK | 1 |
| Vukolova, MN | 1 |
| Kucheryanu, VG | 2 |
| Gudasheva, TA | 1 |
| Jenner, P | 34 |
| O'Neill, MJ | 1 |
| Murray, TK | 1 |
| Whalley, K | 1 |
| Ward, MA | 1 |
| Hicks, CA | 1 |
| Woodhouse, S | 1 |
| Osborne, DJ | 1 |
| Skolnick, P | 1 |
| Storch, A | 1 |
| Hwang, YI | 1 |
| Gearhart, DA | 1 |
| Beach, JW | 1 |
| Neafsey, EJ | 3 |
| Collins, MA | 4 |
| Schwarz, J | 2 |
| Nevet, A | 2 |
| Morris, G | 2 |
| Saban, G | 1 |
| Fainstein, N | 1 |
| Puskovic, V | 1 |
| Wolfe, D | 1 |
| Goss, J | 1 |
| Huang, S | 1 |
| Mata, M | 1 |
| Glorioso, JC | 1 |
| Fink, DJ | 1 |
| Miwa, T | 1 |
| Watanabe, A | 1 |
| Mitsumoto, Y | 1 |
| Furukawa, M | 1 |
| Fukushima, N | 1 |
| Moriizumi, T | 1 |
| Kurkowska-Jastrzebska, I | 4 |
| Litwin, T | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Przybyłkowski, A | 1 |
| Członkowski, A | 3 |
| Członkowska, A | 5 |
| Miller, RM | 2 |
| Callahan, LM | 1 |
| Casaceli, C | 1 |
| Kiser, GL | 1 |
| Chui, B | 1 |
| Kaysser-Kranich, TM | 1 |
| Sendera, TJ | 1 |
| Palaniappan, C | 1 |
| Hershkovitz, Y | 1 |
| Raz, A | 3 |
| Williams, AC | 3 |
| Andringa, G | 2 |
| Drukarch, B | 3 |
| Bol, JG | 1 |
| de Bruin, K | 1 |
| Sorman, K | 1 |
| Habraken, JB | 1 |
| Booij, J | 1 |
| Smeyne, M | 1 |
| Jiao, Y | 1 |
| Shepherd, KR | 1 |
| Gal, S | 1 |
| Fridkin, M | 1 |
| Lloyd, SA | 1 |
| Faherty, CJ | 1 |
| Prou, D | 1 |
| Russo, GS | 1 |
| Rye, DB | 1 |
| Vitek, JL | 1 |
| Muñoz, A | 1 |
| Rey, P | 1 |
| Guerra, MJ | 3 |
| Mendez-Alvarez, E | 1 |
| Soto-Otero, R | 1 |
| Labandeira-Garcia, JL | 3 |
| Dridi, M | 1 |
| Calon, F | 4 |
| Hadj Tahar, A | 2 |
| Meltzer, LT | 1 |
| Luquin, MR | 7 |
| Saldise, L | 2 |
| Guillén, J | 4 |
| Belzunegui, S | 1 |
| San Sebastián, W | 1 |
| Izal, A | 1 |
| Garrido, P | 1 |
| Vázquez, M | 1 |
| Richardson, JR | 1 |
| Caudle, WM | 1 |
| Dean, ED | 1 |
| Pennell, KD | 1 |
| Miller, GW | 1 |
| Braungart, E | 1 |
| Gerlach, M | 2 |
| Riederer, P | 6 |
| Baumeister, R | 1 |
| Hoener, MC | 1 |
| von Bohlen Und Halbach, O | 1 |
| Giorgi, FS | 1 |
| Bandettini di Poggio, A | 1 |
| Battaglia, G | 1 |
| Pellegrini, A | 1 |
| Murri, L | 1 |
| Viaggi, C | 1 |
| Pardini, C | 1 |
| Vaglini, F | 4 |
| Corsini, GU | 4 |
| Schmidt, WJ | 1 |
| Alam, M | 1 |
| Sagi, Y | 1 |
| Amit, T | 1 |
| Cao, XQ | 1 |
| Arai, H | 1 |
| Ren, YR | 1 |
| Oizumi, H | 1 |
| Seike, S | 1 |
| Furuya, T | 1 |
| Yasuda, T | 1 |
| Mizuno, Y | 7 |
| Mochizuki, H | 4 |
| Khan, SZ | 1 |
| Smith, CP | 1 |
| Avila, I | 1 |
| Laurie, C | 1 |
| Reynolds, A | 1 |
| Coskun, O | 1 |
| Bowman, E | 1 |
| Gendelman, HE | 1 |
| Mosley, RL | 1 |
| Sankar, SR | 1 |
| Manivasagam, T | 1 |
| Krishnamurti, A | 1 |
| Ramanathan, M | 1 |
| Anderson, G | 1 |
| Noorian, AR | 1 |
| Taylor, G | 1 |
| Anitha, M | 1 |
| Bernhard, D | 1 |
| Srinivasan, S | 1 |
| Greene, JG | 1 |
| Rojo, AI | 1 |
| Cavada, C | 1 |
| de Sagarra, MR | 1 |
| Cuadrado, A | 1 |
| Knaryan, VH | 1 |
| Butler, JT | 1 |
| Ray, SK | 1 |
| Banik, NL | 1 |
| Wen, L | 1 |
| Wei, W | 1 |
| Gu, W | 1 |
| Huang, P | 1 |
| Ren, X | 1 |
| Zhu, Z | 1 |
| Lin, S | 1 |
| Zhang, B | 1 |
| Zhu, W | 2 |
| Wang, D | 1 |
| Zheng, J | 1 |
| An, Y | 1 |
| Jin, L | 1 |
| Gao, H | 1 |
| Lin, L | 1 |
| Perez, XA | 1 |
| Parameswaran, N | 1 |
| Huang, LZ | 1 |
| O'Leary, KT | 1 |
| Li, WW | 1 |
| Yang, R | 1 |
| Cai, DF | 1 |
| Zhou, XP | 1 |
| Liu, HH | 1 |
| Li, BM | 1 |
| Hu, XW | 1 |
| Li, FQ | 1 |
| You, BM | 1 |
| Chiueh, CC | 7 |
| Markey, SP | 5 |
| Burns, RS | 10 |
| Johannessen, JN | 2 |
| Jacobowitz, DM | 7 |
| Kopin, IJ | 21 |
| Langston, JW | 28 |
| Irwin, I | 9 |
| Langston, EB | 4 |
| Forno, LS | 3 |
| Javitch, JA | 3 |
| Snyder, SH | 4 |
| Lang, AE | 1 |
| Blair, RD | 1 |
| Kolata, G | 1 |
| Lewin, R | 5 |
| Rupniak, NM | 7 |
| Rose, S | 6 |
| Kelly, E | 2 |
| Kilpatrick, G | 2 |
| Lees, A | 1 |
| Marsden, CD | 29 |
| Williams, A | 2 |
| Cohen, G | 2 |
| Pasik, P | 1 |
| Cohen, B | 1 |
| Leist, A | 1 |
| Mytilineou, C | 1 |
| Yahr, MD | 1 |
| Blume, E | 1 |
| Ballard, PA | 1 |
| Wright, JM | 1 |
| Wall, RA | 1 |
| Perry, TL | 2 |
| Paty, DW | 1 |
| Lydén, A | 1 |
| Bondesson, U | 1 |
| Larsson, BS | 1 |
| Lindquist, NG | 1 |
| Denton, T | 1 |
| Howard, BD | 1 |
| Ballard, P | 1 |
| Phillips, JM | 1 |
| Uhl, GR | 1 |
| Maneuf, YP | 1 |
| Mitchell, IJ | 7 |
| Crossman, AR | 20 |
| Woodruff, GN | 2 |
| Brotchie, JM | 6 |
| Singer, TP | 3 |
| Ramsay, RR | 3 |
| Ackrell, BA | 1 |
| Ikebe, S | 1 |
| Hattori, N | 2 |
| Nakagawa-Hattori, Y | 1 |
| Tanaka, M | 1 |
| Ozawa, T | 1 |
| Ohye, T | 1 |
| Ichinose, H | 1 |
| Ogawa, M | 1 |
| Yoshida, M | 4 |
| Nagatsu, T | 5 |
| Rothblat, DS | 7 |
| Akai, T | 1 |
| Ozawa, M | 1 |
| Yamaguchi, M | 1 |
| Mizuta, E | 6 |
| Kuno, S | 7 |
| Guridi, J | 3 |
| Luquin, R | 1 |
| Goulet, M | 4 |
| Blanchet, PJ | 9 |
| Martel, JC | 1 |
| Piercey, MF | 1 |
| Pontieri, FE | 2 |
| Viola, JJ | 2 |
| Sokoloff, L | 5 |
| Porrino, LJ | 6 |
| Johnson, BJ | 1 |
| Peacock, V | 1 |
| Wesemann, W | 1 |
| Grote, C | 1 |
| Clement, HW | 1 |
| Block, F | 1 |
| Sontag, KH | 1 |
| Sawle, GV | 3 |
| Myers, R | 1 |
| Altagracia, M | 2 |
| Rojas, P | 2 |
| Kravzov, J | 1 |
| Boireau, A | 4 |
| Dubédat, P | 3 |
| Bordier, F | 2 |
| Peny, C | 1 |
| Miquet, JM | 2 |
| Durand, G | 1 |
| Meunier, M | 1 |
| Doble, A | 2 |
| Frohna, PA | 2 |
| Joyce, JN | 3 |
| Lidsky, TI | 1 |
| Hawks, T | 1 |
| Mazziotta, JC | 2 |
| Hoffman, JM | 2 |
| Gnanalingham, KK | 3 |
| Hunter, AJ | 3 |
| Erol, DD | 1 |
| Smith, LA | 4 |
| Jiang, ZH | 1 |
| Liu, ZG | 2 |
| Chen, SD | 3 |
| Zhou, WB | 1 |
| Cai, J | 1 |
| Ni, ZM | 1 |
| Zhou, CF | 1 |
| Stoddard, SL | 1 |
| Merkel, GJ | 1 |
| Cook, JA | 1 |
| Zinsmeister, AR | 1 |
| Carmichael, SW | 1 |
| Nomoto, M | 16 |
| Irifune, M | 4 |
| Fukuzaki, K | 1 |
| Fukuda, T | 9 |
| Tomac, A | 1 |
| Lindqvist, E | 1 |
| Lin, LF | 1 |
| Ogren, SO | 1 |
| Young, D | 1 |
| Olson, L | 2 |
| Collier, TJ | 6 |
| Elsworth, JD | 11 |
| Taylor, JR | 8 |
| Sladek, JR | 10 |
| Roth, RH | 11 |
| Redmond, DE | 11 |
| Date, I | 6 |
| Miyoshi, Y | 2 |
| Imaoka, T | 1 |
| Furuta, T | 2 |
| Asari, S | 4 |
| Ohmoto, T | 3 |
| Vermeulen, RJ | 2 |
| Sahadat, MC | 1 |
| Goosen, C | 1 |
| Wolters, EC | 2 |
| Stoof, JC | 2 |
| Sun, ZQ | 1 |
| Roeltgen, DP | 2 |
| Asselin, MC | 2 |
| Soghomonian, JJ | 3 |
| Côté, PY | 2 |
| Parent, A | 6 |
| Yoshimoto, Y | 1 |
| Gohda, Y | 1 |
| Edwards, RH | 1 |
| Gaspar, P | 1 |
| Febvret, A | 1 |
| Colombo, J | 1 |
| Hirsch, EC | 5 |
| Javoy-Agid, F | 4 |
| Agid, Y | 7 |
| Gagnon, C | 2 |
| Gomez-Mancilla, B | 6 |
| Belluzzi, JD | 1 |
| Domino, EF | 7 |
| May, JM | 1 |
| McAfee, DA | 1 |
| Kastner, A | 1 |
| Onofrj, M | 3 |
| Ferracci, F | 1 |
| Fulgente, T | 1 |
| Malatesta, G | 1 |
| Ghilardi, MF | 4 |
| Goddard, M | 1 |
| Signore, AP | 1 |
| Timpson, RL | 1 |
| al-Tikriti, MS | 1 |
| Innis, RB | 2 |
| Wüllner, U | 3 |
| Pakzaban, P | 1 |
| Hantraye, P | 5 |
| Burns, L | 1 |
| Shoup, T | 1 |
| Elmaleh, D | 2 |
| Petto, AJ | 1 |
| Spealman, RD | 3 |
| Brownell, GL | 3 |
| Pedneault, S | 1 |
| Audet, G | 1 |
| Boucher, R | 8 |
| Palmatier, M | 1 |
| Plunkett, RJ | 6 |
| Cummins, A | 1 |
| Oldfield, EH | 6 |
| Pérez-Otaño, I | 1 |
| Oset, C | 1 |
| Del Río, J | 2 |
| Vingerhoets, FJ | 2 |
| Snow, BJ | 3 |
| Tetrud, JW | 9 |
| Schulzer, M | 1 |
| Calne, DB | 5 |
| Karmon, B | 1 |
| Tipton, KF | 4 |
| Lange, KW | 5 |
| Curti, D | 1 |
| Izzo, E | 1 |
| Benzi, G | 2 |
| Imai, H | 6 |
| Endo, K | 2 |
| Yokomizo, K | 1 |
| Murata, Y | 1 |
| Zhou, X | 1 |
| Xu, D | 1 |
| Tang, Q | 1 |
| Xu, X | 1 |
| DiStefano, L | 3 |
| Alexander, GM | 8 |
| Schwartzman, RJ | 8 |
| Grothusen, JR | 5 |
| Gordon, SW | 4 |
| Otto, D | 1 |
| Unsicker, K | 1 |
| Carlsson, A | 2 |
| Blanchette, P | 1 |
| Falardeau, P | 3 |
| DiPaolo, T | 1 |
| Sheng, J | 2 |
| Laguna, J | 2 |
| Yoshimura, N | 1 |
| Sasa, M | 2 |
| Yoshida, O | 1 |
| Mizobuchi, M | 2 |
| Hineno, T | 2 |
| Kakimoto, Y | 2 |
| Hiratani, K | 2 |
| Albanese, A | 3 |
| Granata, R | 2 |
| Gregori, B | 1 |
| Piccardi, MP | 2 |
| Colosimo, C | 2 |
| Tonali, P | 1 |
| Atadzhanov, MA | 6 |
| Nerobkova, LN | 2 |
| Itakura, T | 5 |
| Nakai, M | 3 |
| Nakao, N | 1 |
| Ooiwa, Y | 1 |
| Uematsu, Y | 1 |
| Komai, N | 4 |
| Lessel, J | 1 |
| Davydova, TV | 1 |
| Fomina, VG | 1 |
| Pletsityĭ, KD | 1 |
| Evseev, VA | 1 |
| Krupina, NA | 2 |
| Snow, B | 2 |
| Greenamyre, JT | 2 |
| Eller, RV | 1 |
| Ovadia, A | 4 |
| Kurlan, R | 4 |
| Miletich, RS | 1 |
| Quarantelli, M | 1 |
| Frank, J | 1 |
| Di Chiro, G | 2 |
| Marzatico, F | 1 |
| Café, C | 1 |
| Taborelli, M | 1 |
| Benazzouz, A | 3 |
| Féger, J | 2 |
| Boraud, T | 7 |
| Bioulac, B | 12 |
| Dluzen, D | 1 |
| Jain, R | 1 |
| Brainard, L | 2 |
| Bankiewicz, K | 3 |
| Mandel, RJ | 2 |
| Sofroniew, MV | 1 |
| Tatton, WG | 2 |
| Rinne, JO | 1 |
| Baskin, DS | 1 |
| Browning, JL | 1 |
| Widmayer, MA | 1 |
| Zhu, ZQ | 1 |
| Grossman, RG | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Poirier, J | 4 |
| Thiffault, C | 1 |
| Miyake, H | 1 |
| Peng, MT | 1 |
| Sonsalla, PK | 4 |
| Nicklas, WJ | 2 |
| Heikkila, RE | 5 |
| Mash, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Weiner, WJ | 1 |
| McCrodden, JM | 2 |
| Sullivan, JP | 2 |
| Sandler, M | 3 |
| Glover, V | 1 |
| Clow, A | 1 |
| Jarman, J | 1 |
| Graybiel, AM | 1 |
| Moratalla, R | 2 |
| Quinn, B | 1 |
| DeLanney, LE | 3 |
| Dietz, V | 1 |
| Bodis-Wollner, I | 3 |
| Tagliati, M | 1 |
| Widner, H | 3 |
| Tetrud, J | 3 |
| Rehncrona, S | 3 |
| Brundin, P | 3 |
| Björklund, A | 4 |
| Lindvall, O | 4 |
| Bieganowska, K | 1 |
| Bidziński, A | 1 |
| Mierzewska, H | 1 |
| Korlak, J | 1 |
| Smith, RD | 1 |
| McDermott, M | 1 |
| Braham, J | 1 |
| Oertel, WH | 6 |
| Kupsch, A | 2 |
| Schapira, AH | 1 |
| Hayase, N | 1 |
| Tomiyoshi, K | 1 |
| Watanabe, K | 1 |
| Horikoshi, S | 1 |
| Shibasaki, T | 1 |
| Ohye, C | 1 |
| Bloem, BR | 2 |
| Beckley, DJ | 1 |
| van Vugt, JP | 1 |
| van Dijk, JG | 1 |
| Remler, MP | 1 |
| Roos, RA | 2 |
| Shiosaki, K | 2 |
| Asin, KE | 1 |
| Britton, DR | 3 |
| Lin, CW | 1 |
| Michaelides, M | 1 |
| Smith, L | 4 |
| Bianchi, B | 1 |
| Didomenico, S | 1 |
| Hodges, L | 1 |
| Hong, Y | 1 |
| Mahan, L | 1 |
| Mikusa, J | 1 |
| Miller, T | 1 |
| Nikkel, A | 1 |
| Stashko, M | 1 |
| Witte, D | 1 |
| Williams, M | 2 |
| Tsukahara, T | 1 |
| Takeda, M | 2 |
| Shimohama, S | 1 |
| Ohara, O | 1 |
| Hashimoto, N | 1 |
| Pope-Coleman, A | 2 |
| Nikushkin, EV | 4 |
| Chen, XL | 1 |
| Roisen, FJ | 1 |
| Gupta, M | 1 |
| Maggio, R | 2 |
| Bonuccelli, U | 1 |
| Levy, R | 2 |
| Ruberg, M | 2 |
| Arai, N | 3 |
| Isaji, M | 2 |
| Miyata, H | 1 |
| Fukuyama, J | 1 |
| De Salvia, M | 1 |
| Pastoris, O | 1 |
| Dossena, M | 1 |
| Foppa, P | 1 |
| Catapano, M | 1 |
| Ferrari, R | 1 |
| Dagani, F | 1 |
| Villares, J | 1 |
| Faucheux, B | 1 |
| Pearce, RK | 4 |
| Jackson, M | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Goto, K | 1 |
| Akiyama, H | 1 |
| Chen, Q | 2 |
| Avison, MJ | 3 |
| Feingold, A | 3 |
| Zelanskaya, V | 1 |
| Vaadia, E | 3 |
| Barnéoud, P | 1 |
| Mazadier, M | 1 |
| Parmentier, S | 1 |
| Pollard, HB | 3 |
| Kuijpers, GA | 1 |
| Adeyemo, OM | 3 |
| Goping, G | 1 |
| Burbaud, P | 1 |
| Battino, M | 1 |
| Littarru, GP | 1 |
| Gorini, A | 2 |
| Villa, RF | 2 |
| Elmaleh, DR | 3 |
| Meltzer, PC | 1 |
| Shoup, TM | 1 |
| Fischman, AJ | 2 |
| Madras, BK | 3 |
| Nini, A | 1 |
| Slovin, H | 1 |
| Babich, JW | 1 |
| Barrow, SA | 1 |
| Meltzer, P | 1 |
| Hanson, RN | 1 |
| Sautter, J | 1 |
| Kojima, M | 1 |
| Burov, IuV | 2 |
| Shul'govskiĭ, VV | 2 |
| Petrov, GV | 2 |
| Tereshchenko, LV | 1 |
| Iudin, AV | 1 |
| Fuhr, P | 1 |
| Rioux, L | 1 |
| Tatton, NA | 1 |
| Kish, SJ | 1 |
| Löschmann, PA | 5 |
| Heneka, MT | 1 |
| Schulz, JB | 2 |
| Kunow, M | 3 |
| Wachtel, H | 4 |
| Klockgether, T | 1 |
| Matsumoto, RR | 1 |
| Vu, TQ | 1 |
| Truong, DD | 1 |
| Shikimi, T | 1 |
| Inagaki, T | 1 |
| Kaku, K | 1 |
| Ishino, H | 1 |
| Okunishi, H | 1 |
| Takaori, S | 1 |
| Ekesbo, A | 1 |
| Gunne, LM | 1 |
| Tedroff, J | 2 |
| Lapchak, PA | 1 |
| Collins, F | 2 |
| Hilt, D | 1 |
| Lebel, C | 1 |
| Kryscio, R | 1 |
| Iurasov, VV | 2 |
| Zhigal'tsev, IV | 2 |
| Sandalov, IuG | 1 |
| Kaplun, AP | 1 |
| Shvets, VI | 1 |
| Jordan, S | 1 |
| VanBrocklin, HF | 2 |
| Jagust, WJ | 2 |
| Cools, AR | 1 |
| Bringas, JR | 1 |
| McLaughlin, W | 1 |
| Hundal, R | 1 |
| Yang, B | 1 |
| Imbert, C | 2 |
| Deloire, X | 1 |
| Gross, CE | 7 |
| Perlmutter, JS | 2 |
| Tempel, LW | 1 |
| Black, KJ | 1 |
| Parkinson, D | 1 |
| Todd, RD | 1 |
| Xi, G | 1 |
| Ju, J | 1 |
| Sundström, E | 5 |
| Samuelsson, EB | 1 |
| Cassarino, DS | 1 |
| Fall, CP | 1 |
| Swerdlow, RH | 1 |
| Smith, TS | 1 |
| Halvorsen, EM | 1 |
| Miller, SW | 1 |
| Parks, JP | 1 |
| Parker, WD | 1 |
| Bennett, JP | 1 |
| Marcotte, ER | 1 |
| Chugh, A | 1 |
| Mishra, RK | 1 |
| Johnson, RL | 1 |
| Riva, M | 1 |
| Racagni, G | 1 |
| Kita, S | 1 |
| Iwata, SI | 1 |
| Kaseda, S | 3 |
| Banerji, T | 1 |
| Kanda, T | 3 |
| Jackson, MJ | 2 |
| Nakamura, J | 2 |
| Kase, H | 3 |
| Kuwana, Y | 3 |
| Rozas, G | 2 |
| Liste, I | 1 |
| Brittan, MS | 1 |
| Zea-Ponce, Y | 1 |
| Doudet, DJ | 2 |
| Chan, GL | 1 |
| Holden, JE | 1 |
| McGeer, EG | 1 |
| Aigner, TA | 1 |
| Wyatt, RJ | 1 |
| Ruth, TJ | 2 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| al Moutaery, K | 1 |
| al Deeb, SM | 1 |
| Van Velson, M | 1 |
| Menzaghi, F | 1 |
| Lloyd, GK | 1 |
| Aoi, M | 1 |
| Tomita, S | 1 |
| Taylor, S | 1 |
| Pautot, V | 1 |
| Macaigne, C | 1 |
| Chariot, P | 1 |
| Kohutnicka, M | 3 |
| Lewandowska, E | 1 |
| Konitsiotis, S | 3 |
| Tashiro, T | 1 |
| López-Martín, E | 1 |
| Yu, H | 1 |
| Ferger, B | 4 |
| Spratt, C | 1 |
| Earl, CD | 2 |
| Teismann, P | 3 |
| Kuschinsky, K | 2 |
| Stutzmann, JM | 2 |
| Hyland, K | 1 |
| Arnold, LA | 1 |
| Pettigrew, KD | 1 |
| Iwata, S | 2 |
| Osame, M | 1 |
| Deacon, TW | 1 |
| Hua, S | 1 |
| Reich, SG | 1 |
| Zirh, AT | 1 |
| Perry, V | 1 |
| Dougherty, PM | 1 |
| Lenz, FA | 1 |
| Ni, L | 2 |
| Zhang, H | 2 |
| Kohno, Y | 1 |
| Zhang, M | 1 |
| Avison, C | 1 |
| Deleu, D | 1 |
| Goodwin, BL | 1 |
| Kite, GC | 1 |
| Doan, VD | 1 |
| Brooks, AI | 1 |
| Chadwick, CA | 1 |
| Gelbard, HA | 1 |
| Cory-Slechta, DA | 2 |
| Wrońska, A | 1 |
| Mandir, AS | 1 |
| Wang, ZQ | 1 |
| Simbulan-Rosenthal, CM | 1 |
| Smulson, ME | 1 |
| Hoffman, BE | 1 |
| Guastella, DB | 1 |
| Dawson, VL | 2 |
| Dawson, TM | 2 |
| Mori, A | 1 |
| Jenkins, TA | 1 |
| Wong, JY | 1 |
| Howells, DW | 1 |
| Mendelsohn, FA | 1 |
| Chai, SY | 1 |
| Shimizu, T | 1 |
| Shults, CW | 1 |
| Haas, RH | 1 |
| Borbely, K | 1 |
| Brooks, RA | 1 |
| Wong, DF | 1 |
| Cumming, P | 2 |
| Gjedde, A | 1 |
| Kondo, T | 2 |
| Cass, WA | 1 |
| Lawrence, MS | 2 |
| Tolwani, RJ | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Sewell, RA | 1 |
| Cozzi, NV | 1 |
| Klivenyi, P | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Jiang, D | 1 |
| Almirall, H | 1 |
| Pigarev, I | 1 |
| de la Calzada, MD | 1 |
| Pigareva, M | 1 |
| Sagales, T | 1 |
| Sossi, V | 1 |
| Imperato, A | 2 |
| Moussaoui, S | 2 |
| Verhagen, L | 1 |
| Lamers, E | 1 |
| Jeyarasasingam, G | 1 |
| Steece-Collier, K | 1 |
| Chambers, LK | 1 |
| Jaw-Tsai, SS | 1 |
| Menniti, FS | 1 |
| McCormack, A | 1 |
| Petzinger, G | 1 |
| Janson, AM | 1 |
| Langston, WJ | 1 |
| Ghorayeb, I | 1 |
| Aubert, I | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Tison, F | 1 |
| Jagust, W | 1 |
| Cunningham, J | 1 |
| Budinger, TF | 1 |
| Harvey-White, J | 3 |
| Schroeder, JA | 1 |
| Nash, JE | 1 |
| Fox, SH | 1 |
| Henry, B | 1 |
| Hill, MP | 1 |
| Peggs, D | 3 |
| McGuire, S | 1 |
| Maneuf, Y | 1 |
| Hille, C | 1 |
| He, L | 1 |
| Kirik, D | 1 |
| Rosenblad, C | 1 |
| Georgievska, B | 1 |
| Lundberg, C | 1 |
| Jan, C | 1 |
| François, C | 1 |
| Tandé, D | 1 |
| Yelnik, J | 1 |
| Tremblay, L | 3 |
| Hirsch, E | 1 |
| Eberhardt, O | 1 |
| Coelln, RV | 1 |
| Kugler, S | 1 |
| Lindenau, J | 1 |
| Rathke-Hartlieb, S | 1 |
| Gerhardt, E | 1 |
| Haid, S | 1 |
| Isenmann, S | 1 |
| Gravel, C | 1 |
| Srinivasan, A | 2 |
| Bahr, M | 1 |
| Weller, M | 1 |
| Dichgans, J | 1 |
| Foley, P | 1 |
| Frechter-Mazar, V | 1 |
| Abeles, M | 1 |
| Kliem, MA | 1 |
| Frechilla, D | 1 |
| Cobreros, A | 1 |
| Insausti, R | 1 |
| Luquin, M | 1 |
| Kordower, JH | 1 |
| Costantini, LC | 1 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Turmel, H | 1 |
| Hartmann, A | 1 |
| Parain, K | 1 |
| Douhou, A | 1 |
| Schwaninger, M | 1 |
| Weih, F | 1 |
| Wade, TV | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Poyot, T | 1 |
| Condé, F | 1 |
| Grégoire, MC | 1 |
| Frouin, V | 1 |
| Coulon, C | 1 |
| Fuseau, C | 1 |
| Hinnen, F | 1 |
| Dollé, F | 1 |
| Bottlaender, M | 1 |
| Polonskaya, Y | 1 |
| Gearan, T | 1 |
| Castillo, OA | 1 |
| Stevenson, FF | 1 |
| Schmidt, N | 1 |
| Boyce, S | 10 |
| Steventon, MJ | 2 |
| Iversen, SD | 6 |
| Baron, MS | 1 |
| Ma, D | 1 |
| Leret, ML | 1 |
| San Millán, JA | 1 |
| Fabre, E | 1 |
| Gredilla, R | 1 |
| Barja, G | 1 |
| Giardiniere, M | 1 |
| Morain, P | 1 |
| Duan, W | 1 |
| Ladenheim, B | 1 |
| Cutler, RG | 1 |
| Kruman, II | 1 |
| Cadet, JL | 2 |
| Mattson, MP | 1 |
| Obinu, MC | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Silverdale, MA | 1 |
| Kunikowska, G | 1 |
| Richfield, EK | 1 |
| Thiruchelvam, MJ | 1 |
| Wuertzer, C | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Goldberg, JA | 1 |
| Maraton, S | 1 |
| Haber, SN | 2 |
| Aigner, TG | 1 |
| McLellan, CA | 1 |
| Cohen, RM | 1 |
| Di Monte, D | 2 |
| Metkalova, SE | 1 |
| Kustov, AE | 1 |
| Zang, LY | 1 |
| Misra, HP | 1 |
| Ellis, JE | 1 |
| Byrd, LD | 1 |
| Latulippe, JF | 1 |
| Pope, A | 1 |
| Simpson, K | 1 |
| Taggart, J | 1 |
| Smith, MG | 1 |
| Horowski, R | 1 |
| Jähnig, P | 2 |
| Camarata, PJ | 1 |
| Parker, RG | 1 |
| Park, SK | 1 |
| Haines, SJ | 1 |
| Turner, DA | 1 |
| Chae, H | 1 |
| Ebner, TJ | 1 |
| Tanaka, J | 3 |
| Hasumura, M | 1 |
| Steventon, M | 2 |
| Dupont, J | 1 |
| Elliott, PJ | 2 |
| Walsh, DM | 1 |
| Close, SP | 4 |
| Aziz, TZ | 2 |
| Agarwal, E | 1 |
| Sambrook, MA | 15 |
| Kebabian, JW | 1 |
| DeNinno, MP | 1 |
| Perner, R | 1 |
| Schoenleber, R | 1 |
| Bachurin, SO | 4 |
| Sablin, SO | 1 |
| Lermontova, NN | 4 |
| Solyakov, LS | 1 |
| Dubova, LG | 1 |
| Tkachenko, SE | 4 |
| Dhariwal, K | 2 |
| Levine, M | 2 |
| Markey, CJ | 3 |
| Markey, S | 2 |
| Caohuy, H | 2 |
| Del Zompo, M | 1 |
| Perretta, G | 1 |
| Pifl, C | 3 |
| Schingnitz, G | 3 |
| Hornykiewicz, O | 3 |
| Nishida, J | 1 |
| Takechi, M | 1 |
| Gustavii, B | 1 |
| Fahn, S | 3 |
| Arnaboldi, R | 1 |
| Ghigini, B | 1 |
| Bringmann, G | 1 |
| Friedrich, H | 1 |
| Feineis, D | 1 |
| Kravsov, J | 1 |
| Inami, Y | 1 |
| Salmon, E | 1 |
| Brooks, DJ | 2 |
| Aquilonius, SM | 1 |
| Hartvig, P | 1 |
| Lundqvist, H | 1 |
| Bjurling, P | 1 |
| Långström, B | 1 |
| Bloomfield, PM | 1 |
| Leenders, KL | 1 |
| Page, RD | 1 |
| Zuddas, A | 2 |
| Oberto, G | 1 |
| Fascetti, F | 1 |
| Saporito, M | 1 |
| Basma, A | 1 |
| Geller, HM | 1 |
| McLaughlin, WW | 1 |
| Doty, RL | 1 |
| Goshima, Y | 1 |
| Misu, Y | 1 |
| Misugi, K | 1 |
| Crane, AM | 5 |
| Eden, RJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Gerrard, PA | 1 |
| Harvey, CA | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Owen, DA | 1 |
| Wright, A | 1 |
| Filion, M | 2 |
| Colpaert, FC | 3 |
| Degryse, AD | 3 |
| Van Craenendonck, HV | 1 |
| Brainard, DL | 1 |
| Hichens, M | 2 |
| Nichols, DE | 1 |
| Mailman, RB | 1 |
| Dacko, S | 2 |
| Lavoie, B | 3 |
| Greenwood, CE | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 2 |
| Hsiao, J | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Weiser, M | 1 |
| Fang, J | 1 |
| Gorrod, JW | 1 |
| Hikosaka, O | 2 |
| Popilskis, S | 1 |
| Kostic, V | 1 |
| Levivier, M | 1 |
| Robertson, RG | 5 |
| Graham, WC | 3 |
| Martínez-Lage, JM | 1 |
| Hill, DR | 1 |
| Rettig, KJ | 1 |
| Honoré, T | 1 |
| Turski, L | 1 |
| Felten, SY | 1 |
| Felten, DL | 3 |
| Gibb, WR | 5 |
| Lees, AJ | 4 |
| Mavridis, M | 1 |
| Lategan, AJ | 1 |
| Marien, MR | 1 |
| Kim, MH | 2 |
| Tohgi, H | 1 |
| Abe, T | 1 |
| Takahashi, S | 1 |
| Zhou, XD | 1 |
| Xu, DL | 2 |
| Li, GW | 1 |
| Tang, QM | 2 |
| Xu, XR | 2 |
| de Yébenes, JG | 1 |
| Goodman, R | 1 |
| Jamrosik, Z | 1 |
| Popalski, S | 1 |
| Hayes, AG | 1 |
| Marriott, AS | 3 |
| Rosenfeld, JV | 1 |
| Bartlett, PF | 1 |
| Kerr, RS | 1 |
| Schuette, WH | 1 |
| Cogan, DG | 1 |
| Hogan, N | 1 |
| Nishimoto, A | 2 |
| Usui, S | 1 |
| Fukuda, H | 1 |
| Suzuki, K | 1 |
| Barrio, JR | 1 |
| Huang, SC | 1 |
| Melega, WP | 1 |
| Yu, DC | 1 |
| Satyamurthy, N | 1 |
| Phelps, ME | 1 |
| Landau, WM | 1 |
| Jiménez Jiménez, FJ | 1 |
| Ladero Quesada, JM | 1 |
| Buruma, OJ | 1 |
| Haan, J | 1 |
| Tanner, CM | 2 |
| Golbe, LI | 1 |
| Hassan, MN | 1 |
| Thakar, JH | 1 |
| Grimes, JD | 1 |
| Fujitake, J | 1 |
| Sandyk, R | 2 |
| Iacono, RP | 1 |
| Kay, SR | 1 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Maret, G | 1 |
| Testa, B | 1 |
| el Tayar, N | 1 |
| Carrupt, PA | 1 |
| Rouillard, C | 1 |
| Sturman, SG | 1 |
| Steventon, GB | 1 |
| Waring, RH | 1 |
| Soliakov, LS | 2 |
| Serkova, TP | 2 |
| Petrova, LN | 2 |
| Dranyĭ, OA | 1 |
| Kalashnikov, VV | 2 |
| Clarke, CA | 1 |
| Basciani, M | 1 |
| Martinez-Tica, J | 1 |
| Glover, A | 2 |
| Kamei, I | 2 |
| Nakai, K | 2 |
| Naka, Y | 2 |
| Porrino, L | 1 |
| di Porzio, U | 1 |
| London, WT | 1 |
| Stern, Y | 2 |
| Martin, WR | 2 |
| Kutner, SJ | 1 |
| Palombo, E | 3 |
| Horský, J | 1 |
| Krs, O | 1 |
| Bielavský, J | 1 |
| Allen, JM | 1 |
| Cross, AJ | 3 |
| Yeats, JC | 1 |
| Ghatei, MA | 1 |
| McGregor, GP | 1 |
| Pay, S | 2 |
| Tyers, MB | 1 |
| Crow, TJ | 1 |
| Daigle, M | 1 |
| Savitt, JM | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Radke, JM | 1 |
| Vincent, SR | 2 |
| Terruli, M | 1 |
| Wiener, HL | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Sershen, H | 1 |
| Ueki, A | 1 |
| Chong, PN | 4 |
| Chivers, JK | 1 |
| Jackson, EA | 1 |
| Schultz, W | 4 |
| Scarnati, E | 2 |
| Romo, R | 1 |
| Hadjiconstantinou, M | 1 |
| Mariani, AP | 1 |
| Neff, NH | 1 |
| Yuwiler, A | 4 |
| Temlett, JA | 3 |
| Quinn, NP | 1 |
| Jenner, PG | 2 |
| Pourcher, E | 1 |
| Bonnet, AM | 1 |
| Markstein, R | 1 |
| Lataste, X | 1 |
| Tepper, PG | 1 |
| Horn, AS | 1 |
| LeWitt, PA | 1 |
| Ebert, MH | 1 |
| Pakkenberg, H | 1 |
| Russ, H | 2 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 2 |
| Hammock, BD | 2 |
| Beale, AM | 2 |
| Work, T | 1 |
| Gee, SJ | 1 |
| Gunther, R | 1 |
| Higgins, RJ | 2 |
| Shinka, T | 2 |
| Tye, SJ | 2 |
| Naruse, T | 1 |
| Miyaji, M | 1 |
| Work, TM | 1 |
| Bailey, CS | 1 |
| Smith, MO | 1 |
| Sieber, BA | 1 |
| Manzino, L | 1 |
| Gao, XM | 1 |
| Ku, BS | 1 |
| Chacón, JN | 2 |
| Chedekel, MR | 2 |
| Land, EJ | 2 |
| Truscott, TG | 2 |
| Zagorevskiĭ, VA | 2 |
| Sharkova, LM | 2 |
| Jennings, CA | 1 |
| Loper, AE | 1 |
| Bondi, JV | 1 |
| Hand, E | 1 |
| Stahl, SM | 3 |
| Levi, AC | 1 |
| DeMattei, M | 1 |
| Ravazzani, R | 1 |
| Corvetti, G | 1 |
| Golden, GT | 1 |
| Fariello, RG | 1 |
| Nakamura, H | 2 |
| Kato, S | 2 |
| Clarke, CE | 6 |
| Augood, SJ | 1 |
| Emson, PC | 1 |
| Gugutsidze, DA | 1 |
| Boronina, TA | 1 |
| Garbe, PL | 1 |
| Ruttenber, AJ | 1 |
| Miyoshi, R | 2 |
| Kito, S | 2 |
| Ishida, H | 1 |
| Katayama, S | 1 |
| López Alemany, M | 1 |
| Deutch, AY | 2 |
| Haber, S | 1 |
| Kitt, CA | 1 |
| Cork, LC | 1 |
| Eidelberg, F | 1 |
| Joh, TH | 1 |
| Price, DL | 1 |
| Smith, MT | 1 |
| Sandy, MS | 1 |
| Akos, K | 1 |
| Mizuno, K | 1 |
| Nitta, K | 1 |
| Matsubayashi, H | 1 |
| Yamamura, Y | 1 |
| Tahara, E | 1 |
| Da Prada, M | 1 |
| Kettler, R | 1 |
| Keller, HH | 1 |
| Bonetti, EP | 1 |
| Imhof, R | 1 |
| Ogawa, N | 3 |
| Mizukawa, K | 2 |
| Hirose, Y | 2 |
| Kajita, S | 1 |
| Ohara, S | 2 |
| Watanabe, Y | 2 |
| Lerner, MR | 1 |
| Goldman, RS | 1 |
| Markham, CH | 3 |
| Waters, CM | 2 |
| Hunt, SP | 2 |
| Denaro, FJ | 1 |
| Stahl, S | 1 |
| Dubach, M | 2 |
| Schmidt, RH | 1 |
| Martin, R | 1 |
| German, DC | 2 |
| Bowden, DM | 2 |
| Marshall, JF | 1 |
| Brooks, BA | 3 |
| Fuchs, AF | 1 |
| Finocchio, D | 1 |
| Ricaurte, GA | 1 |
| Backlund, EO | 1 |
| Gerhardt, G | 1 |
| Hoffer, B | 1 |
| Rose, G | 1 |
| Seiger, A | 1 |
| Strömberg, I | 1 |
| Jankovic, J | 1 |
| Xu, XJ | 1 |
| D'Amato, RJ | 2 |
| Frei, B | 1 |
| Richter, C | 1 |
| Narabayashi, H | 4 |
| Finberg, JP | 1 |
| Wells, FR | 1 |
| Barnard, RO | 1 |
| Firnau, G | 1 |
| Nahmias, C | 1 |
| Chirakal, R | 1 |
| Garnett, ES | 1 |
| Schoenberg, DG | 1 |
| Nakakita, K | 1 |
| Garvey, J | 1 |
| Petersen, M | 1 |
| Rose, SP | 1 |
| Hunt, S | 1 |
| Briggs, R | 1 |
| Fine, A | 2 |
| Bond, A | 1 |
| Waters, C | 1 |
| Annett, L | 1 |
| Dunnett, S | 1 |
| Yu, HZ | 1 |
| Wang, ZG | 1 |
| Liang, PF | 1 |
| Doudet, D | 4 |
| Lebrun-Grandié, P | 3 |
| Crampton, JM | 1 |
| Runice, CE | 1 |
| Doyle, TJ | 1 |
| Lau, YS | 1 |
| Wilson, JA | 1 |
| Ho, VW | 1 |
| Riachi, NJ | 1 |
| Arora, PK | 1 |
| Sayre, LM | 1 |
| Harik, SI | 1 |
| Sora, YH | 1 |
| Saitoh, T | 1 |
| Honda, S | 1 |
| Takada, K | 1 |
| Onofrj, MC | 1 |
| Marx, MS | 1 |
| Glover, AA | 1 |
| Askari, S | 1 |
| Speciale, SG | 1 |
| Weingarten, HL | 1 |
| Hood, TW | 1 |
| Greenberg, HS | 1 |
| Brücke, T | 1 |
| Kopin, I | 1 |
| Chung, E | 1 |
| Dvorzniak, M | 1 |
| Bouchard, S | 1 |
| Guttman, M | 2 |
| Yong, VW | 1 |
| Kim, SU | 1 |
| Adam, MJ | 1 |
| Ferraro, TN | 1 |
| Unguez, G | 1 |
| Berg, SC | 1 |
| Nakamura, T | 1 |
| Kebabian, JC | 1 |
| Mak, E | 1 |
| Pate, BD | 1 |
| Bohn, MC | 1 |
| Marciano, F | 1 |
| Cupit, L | 1 |
| Blount, JP | 1 |
| Stoessl, AJ | 1 |
| Nishi, K | 1 |
| Fruncillo, RJ | 1 |
| Lieberman, AN | 1 |
| Nakamura, S | 1 |
| Barsoum, NJ | 1 |
| Gough, AW | 1 |
| Sturgess, JM | 1 |
| de la Iglesia, FA | 1 |
| Doppman, JL | 1 |
| Tsutsumi, T | 1 |
| Jonsson, G | 2 |
| Kulkarni, SK | 1 |
| Mehta, AK | 1 |
| Aley, KO | 1 |
| Shukla, VK | 1 |
| Renkawek, K | 1 |
| Loc'h, C | 1 |
| Tacke, U | 1 |
| Riche, D | 1 |
| Stulzaft, O | 1 |
| Guibert, B | 1 |
| Naquet, R | 1 |
| Mazière, B | 1 |
| Mazière, M | 1 |
| Eidelberg, E | 2 |
| Morgan, WW | 2 |
| Walden, JG | 1 |
| Kokemoor, RH | 1 |
| Schlagmann, C | 1 |
| Remien, J | 1 |
| Hotson, JR | 1 |
| Cheng, BY | 1 |
| Hurley-Gius, K | 1 |
| Ung-Chhun, NA | 1 |
| Pronger, DA | 1 |
| Christensen, MA | 1 |
| Hurley-Gius, D | 1 |
| Hansen, S | 1 |
| Jones, K | 1 |
| Trevor, AJ | 1 |
| Barrow, DL | 2 |
| Fiandaca, MS | 2 |
| Iuvone, PM | 1 |
| Schiff, A | 2 |
| Collins, DC | 2 |
| Kilbourn, MR | 1 |
| Raichle, ME | 1 |
| Welch, MJ | 1 |
| Hirata, Y | 1 |
| Barbeau, A | 3 |
| Dallaire, L | 2 |
| Buu, NT | 2 |
| Veilleux, F | 1 |
| Boyer, H | 1 |
| de Lanney, LE | 1 |
| Strittmatter, SM | 1 |
| Rucinska, E | 1 |
| Eldridge, R | 1 |
| Rocca, WA | 1 |
| Bianchine, JR | 1 |
| McGhee, B | 1 |
| Studer, A | 1 |
| Ono, T | 1 |
| Reynolds, GP | 1 |
| Nakajima, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Leukine (Sargramostim) for Parkinson's Disease[NCT01882010] | Phase 1 | 37 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999[NCT02393027] | Early Phase 1 | 16 participants (Actual) | Interventional | 2015-03-31 | Terminated (stopped due to Enough inclusions for interpretation) | ||
| A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease[NCT03706885] | Phase 1 | 5 participants (Actual) | Interventional | 2018-05-05 | Completed | ||
| [NCT01502384] | 100 participants (Anticipated) | Observational | 2012-01-31 | Not yet recruiting | |||
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease[NCT00909545] | Phase 2 | 99 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease[NCT00129181] | 30 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's[NCT00096720] | Phase 2 | 112 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease[NCT01621581] | Phase 1 | 25 participants (Actual) | Interventional | 2013-03-13 | Completed | ||
| TMS Measures in Parkinson's Disease[NCT00023062] | 80 participants | Observational | 2001-08-31 | Completed | |||
| Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.[NCT00228371] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to insufficent enrolement) | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Deep Brain Stimulation Surgery for Movement Disorders[NCT01581580] | 200 participants (Anticipated) | Interventional | 2011-08-17 | Recruiting | |||
| PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT[NCT00083629] | Phase 1 | 30 participants | Interventional | 2004-05-31 | Completed | ||
| Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease[NCT04650932] | 10 participants (Anticipated) | Interventional | 2022-10-22 | Recruiting | |||
| NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease[NCT00001929] | Phase 2 | 20 participants | Interventional | 1999-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 0 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 3 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 4 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 1 |
Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| Isradipine CR 5mg/Day | 5 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 6 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 3 |
Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 4 |
Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 2 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 7 |
| Isradipine CR 20mg/Day | 4 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 2 |
General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 10 |
| Isradipine CR 20mg/Day | 16 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 0 |
Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 0 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 5 |
| Isradipine CR 20mg/Day | 0 |
The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.60 |
| Isradipine CR 5mg/Day | 3.20 |
| Isradipine CR 10mg/Day | 2.09 |
| Isradipine CR 20mg/Day | 1.86 |
The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.52 |
| Isradipine CR 5mg/Day | 1.99 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 1.50 |
The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.30 |
| Isradipine CR 5mg/Day | 0.76 |
| Isradipine CR 10mg/Day | 0.30 |
| Isradipine CR 20mg/Day | 0.03 |
The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.27 |
| Isradipine CR 5mg/Day | 0.22 |
| Isradipine CR 10mg/Day | 0.12 |
| Isradipine CR 20mg/Day | 0.11 |
The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -5.04 |
| Isradipine CR 5mg/Day | -5.56 |
| Isradipine CR 10mg/Day | -3.69 |
| Isradipine CR 20mg/Day | -3.76 |
The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.58 |
| Isradipine CR 5mg/Day | 0.06 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 0.36 |
The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Isradipine CR 5mg/Day | 3.49 |
| Isradipine CR 10mg/Day | 3.91 |
| Isradipine CR 20mg/Day | 3.69 |
The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.28 |
| Isradipine CR 5mg/Day | 3.47 |
| Isradipine CR 10mg/Day | 3.00 |
| Isradipine CR 20mg/Day | 3.35 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.40 |
| Isradipine CR 5mg/Day | 7.44 |
| Isradipine CR 10mg/Day | 6.30 |
| Isradipine CR 15-20mg/Day | 5.40 |
Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 25 |
| Isradipine CR 5mg/Day | 19 |
| Isradipine CR 10mg/Day | 19 |
| Isradipine CR 20mg/Day | 9 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -0.38 |
| Isradipine CR 5mg/Day | -4.20 |
| Isradipine CR 10mg/Day | -5.14 |
| Isradipine CR 20mg/Day | -4.34 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | 0.09 |
| Isradipine CR 5mg/Day | -2.79 |
| Isradipine CR 10mg/Day | -4.54 |
| Isradipine CR 20mg/Day | -3.63 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| Isradipine CR 5mg/Day | -2.98 |
| Isradipine CR 10mg/Day | -2.29 |
| Isradipine CR 20mg/Day | -1.21 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.42 |
| Isradipine CR 5mg/Day | -0.71 |
| Isradipine CR 10mg/Day | -0.52 |
| Isradipine CR 20mg/Day | 0.18 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -4.77 |
| Isradipine CR 5mg/Day | -9.85 |
| Isradipine CR 10mg/Day | -7.75 |
| Isradipine CR 20mg/Day | -6.30 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -2.45 |
| Isradipine CR 5mg/Day | -8.59 |
| Isradipine CR 10mg/Day | -6.45 |
| Isradipine CR 20mg/Day | -7.01 |
95 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2020 |
Linking microtubules to Parkinson's disease: the case of parkin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Huma | 2015 |
Neurotoxin-based models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, | 2012 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modifie | 2012 |
[Pesticide exposure and Parkinson's syndrome - the epidemiological and experimental evidence].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aryl Hydrocarbon Hydroxylases; Basal Ganglia; Case-Con | 2002 |
Environmental factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Environment; Humans; Nerve D | 2002 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Mode | 2004 |
Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methylation; Niacina | 2005 |
The MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Mod | 2005 |
Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression; Huma | 2005 |
Toxin-induced models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Herbicides; Humans; Neurotox | 2005 |
Modeling neurodegenerative diseases in vivo review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hapl | 2005 |
A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amphetamines; Animals; Disease Models | 2006 |
Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Humans; Nerve Dege | 2006 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dy | 1984 |
Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Cattle; Electron Transport C | 1995 |
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Citric Acid Cycle; DNA, Mitochondrial; | 1995 |
The role of positron emission tomography in the assessment of human neurotransplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Basal Ganglia; Brain Tissue Transplan | 1993 |
Neural degeneration and the transport of neurotransmitters.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Biological Tra | 1993 |
What is it that l-deprenyl (selegiline) might do?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Monoamine Oxidase Inhibitors; Nervous | 1994 |
Glutamatergic drugs in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Excitatory Amino | 1994 |
Thirty years of dopamine research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Dopamine; Humans; Neura | 1993 |
[MPTP--neurotoxin and model substance in Parkinson research].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; MPTP Poisoning; Parkinson Disease, Se | 1994 |
Trophism, transplantation, and animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Disease Models, | 1993 |
Selegiline can mediate neuronal rescue rather than neuronal protection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Isoenzymes; Mice; Mice, Inbred BALB | 1993 |
Nigral degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Mon | 1993 |
Type B monoamine oxidase and neurotoxins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Corpus Striatum; Dopamine; Hum | 1993 |
Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalase; Corpus Striatum; Free Radicals; Glu | 1993 |
Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Humans; MPTP Poisoning; NAD(P) | 1993 |
Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Dopamine Plasma Membrane Tr | 1993 |
Metabolic aspects of the behavior of MPTP and some analogues.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 1993 |
Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Blood Platelets; Corpus Striatum; Humans; Monoamine Ox | 1993 |
Reflex behavior and programming in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electromyography; Haplorhini; Humans; Muscle | 1993 |
Pathophysiology of parkinsonian motor abnormalities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Cerebral Cortex | 1993 |
Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Basal Ganglia; Brain Tissue | 1993 |
Pathogenesis and animal studies of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Humans; Iron; Mito | 1993 |
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
Excitatory amino acids and MPTP toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Excitatory Amino Acids; Huma | 1996 |
[Current aspects of the etiology of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cell Death; Dopamine Agents; Humans; Neurons; Parkinso | 1997 |
The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Functional Laterality; Haplo | 1997 |
[Mitochondrial DNA and Parkinson disease. Methodologic review].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; DNA, Mitochondrial; Humans; MEDLINE; M | 1998 |
A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antioxidants; Blood Pla | 1999 |
[MPTP parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diagnosis, Differential; Humans; Monoa | 1999 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Death; Dopamine; Dopami | 2000 |
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Cell Survival; Corpus Striatum; | 2000 |
The motor circuit of the human basal ganglia reconsidered.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Globus Pallid | 2000 |
Neurochemical findings in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2001 |
Astrocytes and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biotransformation; Dopamine; Glio | 1992 |
The MPTP-treated mouse as a model of parkinsonism: how good is it?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Eval | 1992 |
Trichloroharmanes as potential endogenously formed inducers of Morbus Parkinson: synthesis, analytics, and first in vivo-investigations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbolines; Humans; Molecular Structur | 1992 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Fema | 1992 |
Pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Humans; Parkinson Disease; Parkinson Di | 1992 |
Mitochondrial mechanisms of neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformatio | 1992 |
[Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Guinea Pigs; H | 1991 |
The neuronal mechanism underlying parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Cats; Caudate Nucleus; Dyskine | 1991 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Primate models of movement disorders of basal ganglia origin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia Diseases; Disease Models, Anima | 1990 |
Pyridine derivatives: structure-activity relationships causing parkinsonism-like symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; MPTP Poisoning; Parkinson Disease, Se | 1991 |
Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Carotid Art | 1991 |
[Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1991 |
Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Callithrix; Chlorocebus aethiops; Corp | 1991 |
Oxidative stress as a cause of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Dopamine; Humans; Iron; | 1991 |
[Parkinson's disease; etiology and animal model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport; H | 1991 |
[Aging and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aging; Animals; Humans; Mice; Middle Aged | 1991 |
Clinical neuromythology VII. Artificial intelligence: the brain transplant cure for parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Artificial Intelligence; Cau | 1990 |
[An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Dogs; Guinea Pigs; Humans; Macaca mulat | 1990 |
Biochemical aspects of drug-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Monoamine Oxi | 1990 |
The neurotoxicity of MPTP and the relevance to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; MPTP Poisoning; Parkinson Disease, Se | 1990 |
The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Parkinson Dis | 1990 |
Do environmental toxins cause Parkinson's disease? A critical review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Amyotrophic Lateral Sclerosis; Environmen | 1990 |
The genetics of Parkinson's disease: a reconsideration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Diseases in Twins; Genes; Humans; Mitochondria; Parkin | 1990 |
The hypothalamus in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Hypothalamus; Parkinson Disease, Secondary | 1990 |
The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Chemical Phenomena; Chemistry; Humans; Monoamine Oxida | 1990 |
The role of environmental toxins in the etiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Hazardous Substances; Humans; Middle Aged; Park | 1989 |
[Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 1989 |
Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Mice; Neurotoxins; | 1989 |
[MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease, Secondary | 1989 |
[Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Mice; Mitochondria; Nerve | 1989 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopa | 1988 |
MPTP effects on dopamine neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Amines; Brain; Des | 1988 |
[MPTP and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Designer Drugs; Disease Models, Animal | 1988 |
[The neurotoxic effect of MPTP and its mechanisms].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Designer Drugs; Humans; Parkinson Disease, Se | 1988 |
MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aging; Animals; Binding Sites; Disease Models, | 1986 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levo | 1987 |
MPTP in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Mice; Par | 1988 |
MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Parkinson | 1988 |
MPTP toxicity: implications for research in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Haplorhini; Humans; Melanins; Mitochondria; M | 1988 |
Early parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Diagnosis, Differential; Humans; Parkinson Disease; Pa | 1986 |
[A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Dopamine; Levodopa; Locomotion; | 1987 |
MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Blood-Brain Barr | 1987 |
[Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Catecholamines; Chemical | 1986 |
MPTP: current concepts and controversies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Parkinson Disease, Secondary; | 1986 |
The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Disease Susceptibili | 1987 |
MPTP: insights into the etiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease; Parkinson Disease, Secondar | 1987 |
6 trials available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphen | 1992 |
Fetal-tissue transplants in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain Chemistry; Caudate Nucleus; Dopamine; Fetal Tiss | 1992 |
Big first scored with nerve diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levo | 1989 |
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; F | 1989 |
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; H | 1987 |
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as | 1985 |
698 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1986 |
Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Blotting, Western; Chroni | 2022 |
TGR5 Agonist INT-777 Alleviates Inflammatory Neurodegeneration in Parkinson's Disease Mouse Model by Modulating Mitochondrial Dynamics in Microglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cholic Acids; Di | 2022 |
Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopaminerg | 2022 |
Wuzi Yanzong pill attenuates MPTP-induced Parkinson's Disease via PI3K/Akt signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Brain-Derived | 2022 |
Effects of eugenol on the behavioral and pathological progression in the MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Disea | 2022 |
Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Dopamin | 2022 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Exercise training has a protective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model with improved neural and intestinal pathology and modified intestinal flora.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Anti-oxidative and anti-neuroinflammatory role of Necrostatin-1s and docosahexaenoic acid in RIP-1-mediated neurotoxicity in MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Docosah | 2023 |
Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson's disease monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2019 |
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Basal Ganglia; Bl | 2019 |
Mercury sulfide-containing Hua-Feng-Dan and 70W (Rannasangpei) protect against LPS plus MPTP-induced neurotoxicity and disturbance of gut microbiota in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Dopaminergic Neurons; Lipopolysacchari | 2020 |
MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease by regulating inducible nitric-oxide synthase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Humans; Insulin-Like Growth | 2020 |
Sodium Butyrate Exacerbates Parkinson's Disease by Aggravating Neuroinflammation and Colonic Inflammation in MPTP-Induced Mice Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Butyric Acid; Cell Line; Colon; C | 2020 |
Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Autophagy-Related | 2021 |
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; | 2020 |
Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Colon; Dopaminergic Neurons; Dysbios | 2021 |
Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzofurans; Body Weight; Disease Models, Ani | 2021 |
MicroRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Dopaminergic Neur | 2021 |
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line, Tumor; Crystallography, X-R | 2021 |
Behavioral characterization in MPTP/p mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2021 |
Neuropeptide-S affects cognitive impairment and depression-like behavior on MPTP induced experimental mouse model of Parkinson’s disease
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition; Depression; Disease Models, Animal | 2021 |
Protective function of SLC30A10 induced via PERK-ATF4 pathway against 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Activating Transcription | 2017 |
Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Gene Expression Regulation; | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Stri | 2018 |
MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Gene Expre | 2018 |
Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Differentiation; Corpus Striatum; Diseas | 2018 |
Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporins; Disease Models, Animal; Dopaminer | 2018 |
Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Cell Line; Disease | 2018 |
Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in Drosophila melanogaster.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Antioxidants; Behavior, | 2018 |
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Delayed-Action Preparations; | 2018 |
1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Choline O-Acetyltransferase; Disease Models, | 2018 |
Calycosin attenuates MPTP-induced Parkinson's disease by suppressing the activation of TLR/NF-κB and MAPK pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Dopaminergic Neurons; Inflam | 2019 |
Neuroprotective effect of naringenin against MPTP-induced oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalase; Corpus Striatum; Dose-Response Rela | 2019 |
NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Inflammasomes; Male; Mice, I | 2019 |
Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Corpus Striatum; | 2019 |
Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Male | 2013 |
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2013 |
The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Brain | 2013 |
Cerebral metabonomics study on Parkinson's disease mice treated with extract of Acanthopanax senticosus harms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Disease Models, Animal; Dopamine; | 2013 |
[Changes of glucose in the brains of monkeys with MPTP induced Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Fluorodeoxyglu | 2013 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Nucleus; Corpus Striatum; Cysteine; Dopa | 2014 |
Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; alpha-Synuclein; Animals; | 2013 |
[Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acrylamides; Animals; | 2013 |
Tat-fused recombinant human SAG prevents dopaminergic neurodegeneration in a MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Line, Tumor; Dopaminergic Neu | 2014 |
Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigen Presentation; Astroc | 2015 |
Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Apomorphine; Basal Ganglia; Benzazepin | 2015 |
Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Cerebral Cortex; Corpus Striat | 2015 |
Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-κB-dependent inflammation process in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Cell Line, Tumor; | 2015 |
Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: A microarray study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Proliferation; Disease Models, Animal; D | 2015 |
Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Corpus Striatum; Dopaminergic N | 2015 |
Ginsenoside Rg1 Ameliorates Motor Function in an Animal Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2015 |
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anisoles; Astrocytes; Cell Death; Disease Mod | 2015 |
Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Asymptomatic Diseases; Corpus Striatum; Male; | 2015 |
Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2016 |
c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cell Death; Dopaminergic | 2016 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, A | 2016 |
TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Disease Models, | 2016 |
Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Corpus Str | 2016 |
Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Signaling; Coordination Complexes; Di | 2016 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2016 |
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Aged; Animals; Biomarkers; Corpus Stria | 2016 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholin | 2016 |
Protective effects and mechanisms of Ndfipl on SH-SY5Y cell apoptosis in an in vitro Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Apoptosis; Carrier Proteins; Cell Sur | 2016 |
Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; DNA; Dopamine; | 2016 |
The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; alpha-Synuclein; Animals; Autophagy; Beha | 2016 |
Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Channel Blockers; Calcium Channels, L | 2016 |
Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Aged; Aged, 80 and over; Animals; B | 2016 |
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Cytokines; Disease Model | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2016 |
α-lipoic acid exerts neuroprotective effects on neuronal cells by upregulating the expression of PCNA via the P53 pathway in neurodegenerative conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport Co | 2016 |
Injury-stimulated Sonic hedgehog expression in microglia contributes to neuroinflammatory response in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Disease Models, Animal; Hedg | 2017 |
Early upregulation of 18-kDa translocator protein in response to acute neurodegenerative damage in TREM2-deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Carrier Proteins; Disease Mode | 2017 |
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biphenyl Compounds; Corpus Striatum; Disease | 2017 |
Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; | 2008 |
GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Female; Glial Cell Line-Deri | 2008 |
Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, | 2008 |
Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ataxia; Corpus Striatum; Free Radical Scaveng | 2008 |
Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphatases; alpha-Synuclein; Animals; A | 2008 |
Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Catalysis; Cattle; Deuterium; | 2008 |
[Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cyclooxygenase 2; Ginsenos | 2008 |
MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Dopamine Agents; Gastrointest | 2008 |
[Effect of phosphorylated-ERK1/2 on inducible nitric oxide synthase expression in the substantia nigra of mice with MPTP-induced Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Extracellular Signal-Regulated MAP Kinases; G | 2009 |
Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Cell Survival; Ce | 2009 |
Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Copper Sulfate; Dopamine; | 2009 |
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoxazines; Cannabinoid Receptor Agonists; | 2009 |
Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Anim | 2010 |
MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute-Phase Proteins; Animals; C-Reactive Protein; Dop | 2009 |
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Age Factors; Animals; Cell Line; Disease | 2009 |
Altered AMPA receptor expression with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Corpus Striatum; Disease Model | 2010 |
Striatal spine plasticity in Parkinson's disease: pathological or not?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Corpus Striatum; Dendritic S | 2009 |
Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Glial Cell | 2009 |
[Effection of Qing-Xuan tablets on behavior pattern and striatal TNF-alpha of Parkinson model mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2009 |
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Dopamine; Male; Mi | 2010 |
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Depre | 2010 |
Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents, Second-Generation; Blo | 2010 |
[Modeling of preclinical and early clinical stages of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2010 |
Computational physiology of the basal ganglia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Chlorocebus | 2010 |
Running wheel activity restores MPTP-induced functional deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain-Derived Neurotrophic Factor; Chr | 2011 |
Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Disease Models, Animal; | 2010 |
Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [¹⁸F]fallypride.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Benzamides; Blotting, W | 2010 |
The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Docosahexaenoic Acids | 2010 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Corpus | 2010 |
[Effects of SV heat-resisting protein on the microglial cells in MPTP-treated mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Female; Male; Materia Medica; Mice; Mice, Inb | 2009 |
[The effect of TSPG in vivo on transplantation of neural stem cells in treatment of Parkinson's disease mouse].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Combined Modality Therapy; Humans; Male; Mice | 2009 |
[Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Corpus Striatum; Disease Models, | 2010 |
Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of dopaminergic loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; DNA-Bindi | 2011 |
[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Antiparkinson Agents; Disease Mod | 2011 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid D | 2011 |
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line; Disease Models, Animal; Fem | 2012 |
PEP-1-heat shock protein 27 protects from neuronal damage in cells and in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cell | 2012 |
Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Apoptosis; Apoptosis Regulatory | 2012 |
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyloid beta-Protein Precursor; Anima | 2012 |
Physical activity is linked to ceruloplasmin in the striatum of intact but not MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ceruloplasmin; Corpus Striatum; Female; Macac | 2012 |
Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; alpha-Synuclein; Animals; Disease Models | 2012 |
[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2012 |
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Amides; Animals; Corpus Striatum | 2002 |
Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Ketones; Ligands; Mice; Mole | 2002 |
Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Body Weight; Carotenoids | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2002 |
Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Azetidines; Brain Chemistry; | 2002 |
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; DNA, Complementary; Dopamine Agents; I | 2002 |
[Possible mechanisms of the protective effect of ginsenoside Rg1 on apoptosis in substantia nigra neurons].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Caspases; Ginsenosides; | 2002 |
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzimidazoles; Dopamin | 2003 |
Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Chronic Disease; Corpus Striat | 2003 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dehydroepiandrosterone; Dopamine Agents; Dose | 2003 |
Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine Agents; Female; Im | 2003 |
Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Cells, Cultured; Coculture Techni | 2003 |
Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Coculture Techniques; Dopamine; Drug Synergis | 2003 |
Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Nucleus; Dopamine; Dopamine A | 2003 |
Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carotid Arteries; Cor | 2003 |
Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bridged Bicyclo Compounds; Dop | 2003 |
COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Dopamine Agents; Genotype; | 2003 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamin | 2003 |
Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Brain Mapping; Cerebr | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Basal Ganglia; Brain; Brain | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkin | 2003 |
Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Dose-Response Relationship, | 2003 |
Dipeptide analog of neurotensin active site prevents the development of experimental Parkinson's syndrome in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Cell Membrane; Dopamine Agents | 2003 |
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dose | 2004 |
Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cell Line; Ce | 2004 |
Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agents; Dopamine Agonis | 2004 |
Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Female; Gene E | 2004 |
Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Disease Models, | 2004 |
Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Blotting, Western; | 2004 |
Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Cycle; Cell Death; Chronic Disease; Cyto | 2004 |
Physiological studies of information processing in the normal and Parkinsonian basal ganglia: pallidal activity in Go/No-Go task and following MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Chlorocebus | 2005 |
Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cocaine; Dopamine Agents; Dopamine Plasma Mem | 2005 |
Glia cell number modulates sensitivity to MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antimetabolites; Bromodeoxyuridine; Cell Coun | 2005 |
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amines; Animals; Brain; Corpus Striatum; Dopamine; Dru | 2005 |
Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cocaine; DNA Primers; Dopamine Ag | 2006 |
Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Analysis of Variance; Animals; Apom | 2006 |
Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin-Converting Enzyme Inhibitors; Animals; Ant | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; | 2006 |
Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Cell Death; Dop | 2006 |
Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Dieldrin; Disease Models, A | 2006 |
Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Caenorhabditis elegans; | 2004 |
Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enz | 2006 |
Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cell Survival; Cells, Cult | 2007 |
Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Cell Death; Dopam | 2006 |
Mitochondrial complex-1 in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Electron Transport Complex I; Humans; Lymphocytes; Par | 2006 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; Antineoplastic Combined Ch | 2007 |
The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Male; Medicine, Ayurvedic; Mesencephalon; Mic | 2007 |
Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Cell Count; Colon; Dopamine; | 2007 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine Plasma Membrane Tra | 2008 |
Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Biogenic Monoa | 2008 |
Effect of (R)-salsolinol and N-methyl-(R)-salsolinol on the balance impairment between dopamine and acetylcholine in rat brain: involvement in pathogenesis of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Acetylcholinesterase; Animals; Brain; C | 2008 |
Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Electric Stimulati | 2008 |
[Protective effects of Cistanche total glycosides on dopaminergic neuron in substantia nigra of model mice of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cistanche; Dopamine; Drugs, | 2008 |
[Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Chromatography, High Pressure Li | 2007 |
Parkinson's disease, 1984.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Levodopa; Parkinson Disease; Parkinso | 1984 |
Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Guinea Pig | 1984 |
Pargyline prevents MPTP-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Male; Neurons; Pargyline; Pa | 1984 |
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Guinea | 1984 |
Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; I | 1984 |
Monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Cats; Disease Models, Animal; Haplorhi | 1983 |
Trail of ironies to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1984 |
Street-drug contaminant causing parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Drug Contamination; Humans; Illicit Drugs; Meperidine; | 1984 |
Brain enzyme is the target of drug toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Brain; Haplorhini; Humans; Mic | 1984 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1984 |
MPTP parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Humans; Male; Mice; Parkinson Disease, | 1984 |
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Female; Homovanill | 1984 |
Street drugs yield primate Parkinson's model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Disease Models, Animal; Humans; Illici | 1983 |
Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Chemical Phenomena; Chemistry; Humans; Male; Middle Ag | 1983 |
Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Adult; Chronic Disease; Hu | 1984 |
Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cattle; Eye Proteins; Humans; In Vitro Techni | 1983 |
Inhibition of dopamine uptake by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a cause of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Gland Neoplasms; Animals; Biological Transport | 1984 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucina | 1984 |
The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Brain; Dopamine; Hum | 1984 |
Leads from the MMWR. Street-drug contaminant causing parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Drug Contamination; Humans; Illicit Drugs; Meperidine; | 1984 |
Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Autoradiography; Binding Sites; Brain; | 1984 |
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Arrhythmia Agents; Basal Ganglia; Benzof | 1995 |
Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Glands; Animals; Base Sequence; Locus Coeruleu | 1995 |
Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Cell Count; Chronic Disease; Corpus Str | 1995 |
Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Disease Models | 1995 |
Subthalamotomy improves MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Macaca mulatta; Parkinson Disease, Secondary; | 1994 |
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Stri | 1995 |
Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Corpus Striatum | 1995 |
Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine D2 R | 1995 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; A | 1993 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cats; Corpus Striatum; Mazin | 1995 |
Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cognition; Dopamine Agonist | 1995 |
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Behavior, Animal; Callithr | 1995 |
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 1995 |
[Fate of human fetal dopamine neurons transplanted into rhesus monkey model of Parkinson's disease: a tyrosine hydroxylase immunocytochemical study].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Corpus Striatum | 1995 |
Adrenal medulla and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; D | 1994 |
Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressiv | 1994 |
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Glial Cell Line-Derived Neurotrophi | 1995 |
Peripheral nerve-dopamine neuron co-grafts in MPTP-treated monkeys: augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Dopamine; Fetal Tissue | 1994 |
Efficacy of pretransection of peripheral nerve for promoting the survival of cografted chromaffin cells and recovery of host dopaminergic fibers in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Cell Survival; Cell Transpla | 1994 |
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agoni | 1994 |
Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine Agonists; Dose-Respons | 1994 |
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; A | 1994 |
Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Enkephalins; Gene | 1994 |
Long-term effects of cografts of pretransected peripheral nerve with adrenal medulla in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Cell Survival; Corpus Striat | 1993 |
Serotonergic sprouting in primate MTP-induced hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Cebus; Dopamine; Dopa | 1993 |
Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Choline O-Acetyltransferase; Dopa | 1993 |
Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Behavior, Animal; Brain Chem | 1993 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Domina | 1994 |
Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; G(M1) Ganglioside; Levodopa; Macaca | 1994 |
Spontaneous functional recovery from parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Corpus Striatum; Dopamine; Female; Immu | 1994 |
Effects of drug manipulations on anterior components of somatosensory evoked potentials in a parkinsonian animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cholinergic Antagonists; Electric Stimulation | 1994 |
Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Gland Neoplasms; Adrenal Medulla; Animals; Cap | 1994 |
Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: correlation with improved behavioral function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Tissue Transplantation | 1994 |
Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Carbon Radioisotopes; Caudate Nucleus; Cocaine; Dopami | 1994 |
Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Axons; Corpus Striatum; Gene | 1994 |
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pall | 1994 |
Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amnion; Animals; Apomorphine; Caudate Nucleus; Cerebra | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihyd | 1994 |
The primate subthalamic nucleus. I. Functional properties in intact animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Basal Ganglia; Brain Mapping; Cere | 1994 |
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Basal Ganglia; Brain Mappi | 1994 |
The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Bicuculline; Brain Mapping | 1994 |
Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Brain; Choline O-Acetyl | 1994 |
Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Caudate Nucleus; Iron; Macaca | 1994 |
Parkinsonism induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cats: behavioral, biochemical and pathological studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catecholamines; Cats; Disea | 1993 |
Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Caudate Nucleus; Corpus Striatum; Dopam | 1994 |
Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Blood-Brain Barrier; Female; Lev | 1994 |
FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Dopamine; Enzyme-Linked Immunosor | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidop | 1993 |
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Callithri | 1993 |
N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Diz | 1993 |
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopa | 1993 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1993 |
Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Binding Sites; Dopamine Age | 1993 |
Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Glands; Adrenocorticotropic Hormone; Animals; | 1993 |
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Bromocriptine; Callithrix; Dopamine | 1993 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Clinical and preclinical PET correlates of parkinsonism with 11C-WIN 35,428.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbon Radioisotopes; Cocaine; Humans; Parkin | 1994 |
[The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; C | 1993 |
Transplantation of autologous cervical sympathetic ganglion into the brain with Parkinson's disease: experimental and clinical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Animals; Corpus Striatum; Female; Humans; | 1994 |
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 1994 |
[Decrease in motor activity in C57Bl/6 mice as affected by lymphocytes taken from animals with Parkinsonian syndrome induced by 1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; B-Lymphocytes; Immunotherapy, Adoptive; Male; | 1994 |
Parkinsonism caused by petroleum waste ingestion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Humans; Male; Parkinson Diseas | 1994 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvuls | 1994 |
MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Blood-Brain Barrier; Ca | 1994 |
Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Caudate Nucleus; Dihydr | 1993 |
Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Electric Stimulation Therap | 1993 |
Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Drug Implants; Lev | 1994 |
Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodop | 1993 |
Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Ca | 1994 |
A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Calli | 1993 |
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Callith | 1993 |
Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Calcium; Calcium Channels; Cell Death; | 1993 |
The neuronal mechanism underlying parkinsonism and dyskinesia, and differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bicuculline; Cats; Caudate Nucle | 1993 |
Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Mapping; Caudate Nucle | 1993 |
The visual system in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Contrast Sensitivity; Dopamine; Electroenceph | 1993 |
Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activities of Daily Living; Adult; Brain Tissue Transp | 1993 |
Immunological changes in the MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibody-Producing Cells; Cell Migration Inhi | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, | 1993 |
Parkinsonian tremor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease, Secondary; Tremor | 1993 |
Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System Stimulants; Corpus Str | 1995 |
Long latency postural reflexes are under supraspinal dopaminergic control.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Age of Onset; Antiparkinson Agents; Antipsychot | 1995 |
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 1996 |
Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain-Derived Neurotrophic Factor; Mac | 1995 |
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Discrimination Learning; | 1995 |
[Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cricetinae | 1995 |
[Effect of basic fibroblast growth factor on development of Parkinson syndrome in mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Fibroblast Growth | 1995 |
The effect of prior in vitro exposure of donor cells to trophic factors in neurotransplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Differentiation; Cricetinae; Cyclosporin | 1996 |
Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Female; Globus Pallidus; Glu | 1996 |
Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Dopamine; Dopamine Agents; E | 1996 |
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chore | 1996 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; | 1995 |
An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiemetics; Antiparkin | 1996 |
Biochemical evaluations in skeletal muscles of primates with MPTP Parkinson-like syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport Co | 1995 |
Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Globus Pallidus; Glu | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1995 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Ferritins; Immunohistochemistry; | 1996 |
Alterations in pallidal neuronal responses to peripheral sensory and striatal stimulation in symptomatic and recovered parkinsonian cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Behavior, Animal; Brain Ch | 1995 |
Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Female; Levo | 1996 |
Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Chlorocebus aethiops; Conditio | 1996 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Ce | 1996 |
The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Compartmentation; Cell | 1996 |
Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dominance, Cerebral; El | 1996 |
Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cerebral Cortex; Dihydroergotoxine; El | 1996 |
Cocaine congeners as PET imaging probes for dopamine terminals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbon Radioisotopes; Cocaine; Dopamin | 1996 |
Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electrophysiology; Globus Pallidus; Macaca mu | 1995 |
SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Carrier Proteins; Cocaine; Con | 1997 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Amines; Calcium Ch | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 1996 |
[Operant behavioral disorders in monkeys with an MPTP-induced Parkinson-like syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Conditioning, Operant; Dopa | 1995 |
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain | 1997 |
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain | 1997 |
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain | 1997 |
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain | 1997 |
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Aromat | 1997 |
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acridine Orange; Animals; Apoptosis; Cats; Cell Nucleu | 1997 |
Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Disease Models, Animal; Dopamin | 1997 |
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agonists; Drug Interact | 1997 |
Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Dopamine; Dopamine A | 1997 |
Nullification of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alpha-Globulins; Animals; Antiparkinson Agents; Brain; | 1997 |
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Dopamine Antagonists; | 1997 |
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ven | 1997 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopami | 1997 |
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Benzazepin | 1997 |
[The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 1997 |
PET studies of functional compensation in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Progression; Dopamin | 1997 |
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Chron | 1997 |
Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1998 |
Application of gene therapy for Parkinson's disease: nonhuman primate experience.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta-Galactosidase; Blood-Brain Barrier; Brai | 1998 |
Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Corpus Striatum; Dopamine; Glial C | 1998 |
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Dis | 1997 |
MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Dopamine Agents; Dystonia; | 1997 |
Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Caudate Nucleus; Dopamine Ag | 1997 |
[Effect of acupuncture and Chinese medicine treatment on brain dopamine level of MPTP-lesioned C57BL mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acupuncture Therapy; A | 1996 |
Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dopamine; | 1997 |
Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Drug Administration Schedule | 1997 |
Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Catalase; Disease Models | 1997 |
Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1998 |
Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cells, Cul | 1997 |
Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cabergoline; Callithrix; Do | 1998 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr | 1998 |
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 1998 |
Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; M | 1998 |
Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzofurans; Brain Tissue Tr | 1998 |
6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 1998 |
Effect of chronic administration of magnesium sulfate on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Dopamine; Dopamine Agents; D | 1998 |
Glutamatergic compensatory mechanisms in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agonists; Kynurenic Acid; Macaca fas | 1998 |
Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dose-Response Relations | 1998 |
GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Dopamine; Glial | 1998 |
A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1998 |
Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopamine; | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
Adenosine A2A receptors modify motor function in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Callithrix; Dopamine; Female; Male | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatu | 1998 |
[Behaviour after transplantation of brain cells into monkey models of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Fet | 1997 |
Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cardiotonic Agents; Cyclic N-Oxi | 1998 |
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Mo | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
[Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Aged; Animals; Antiparkinso | 1998 |
Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbon Radioisotopes; Corpus Striatum; | 1998 |
The role of the thalamus and basal ganglia in parkinsonian tremor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Feedback; Par | 1998 |
Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzothiazoles; Dopamin | 1998 |
MPTP-Induced pallidal lesions in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Chronic Disease; Female | 1999 |
Endogenous dopamine-derived neurotoxins and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Dopamine; Humans; Isoquinolines; M | 1998 |
Environmental MPTP as a factor in the aetiology of Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Environmental Pollutants; Gas Chromatography-Mass Spec | 1998 |
Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carrier Proteins; Cats; Cau | 1999 |
D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Female; Levodopa; Locomotio | 1999 |
Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Corpus Striatum | 1999 |
MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Genes, MHC Class I; Histocyt | 1999 |
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; DNA Damage; Enzy | 1999 |
Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Levodopa; Locomotion; Macaca f | 1999 |
Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; Animals; Dopamine Agents; E | 1999 |
Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin-Converting Enzyme Inhibitors; Animals; Cor | 1999 |
[Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Intran | 1999 |
Principal component analysis of the dynamic response measured by fMRI: a generalized linear systems framework.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Dopamine Age | 1999 |
Metabolism of adenosine increase in the striatum in common marmoset parkinsonism induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Callithrix; Corpus Striatum; Extra | 1999 |
Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug | 1999 |
NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum | 1999 |
Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 1999 |
Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blinking; Caudate Nucleus; Chlorocebus aethio | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
More about parkinsonism after taking ecstasy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Basal Ganglia; Dopamine Agents; Hallucinogens; Humans; | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Nocturnal sleep structure and temperature slope in MPTP treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Temperature; Corpus Striatum; Dopamine A | 1999 |
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Disea | 2000 |
Pattern of dopaminergic loss in the striatum of humans with parkinsonism induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cell Death; Corpus Striatum; Dopamine; Humans; Neurons | 2000 |
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Female; Humans; Male; Middle A | 2000 |
Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electr | 2000 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, An | 2000 |
Nicotinic receptors and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Drug Interact | 2000 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catal | 2000 |
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbido | 2000 |
Striatal enkephalin gene expression does not reflect parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Caudate Nucleus; Corp | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2000 |
Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Disease Mod | 2000 |
Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Dopamine Agents; F | 2000 |
Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Chlorocebus aethiops; Dopamine; Globus | 2000 |
Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Apoptosis; Caspase Inhibitors; | 2000 |
Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Excitatory Amino Acid Antagonists; Glutamic A | 2000 |
Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2001 |
Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carrier Proteins; Dopamine | 2001 |
Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autor | 2001 |
Gene therapy to the rescue in Parkinson's disease. Response from Kordower and Aebischer.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine Agents; Genetic Therapy; Glia | 2001 |
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Binding, Competitive; Catecholam | 2001 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Caspases; Disease Model | 2001 |
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Biotransformation; Dopam | 2001 |
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carrier Proteins; Dopam | 2001 |
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cognition Disorders; Corpus | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; DNA, Compl | 2001 |
Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carbon Radioisotopes; | 2001 |
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Binding, Comp | 2001 |
The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Dopamine; Dopamin | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; BH3 Interacting Domain Death Agonist Protein; | 2001 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Dopamine Agonists; History, | 2001 |
Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Behavior, Animal; Disease | 2002 |
Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2002 |
Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Conditioning, Operant; D | 2002 |
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Survival; Corpus Stri | 2002 |
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2002 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Bindin | 2002 |
[Treatment of neurodegenerative diseases: new perspectives].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Corpus Striatum; De | 2001 |
The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Copper; Disease Models, Animal | 2002 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior | 2002 |
Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Arm; Biomechanical Phenome | 2002 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; | 1992 |
[The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Behavior, Animal; Cholineste | 1992 |
EPR kinetic studies of superoxide radicals generated during the autoxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium, a bioactivated intermediate of parkinsonian-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; | 1992 |
A method for quantitating motor deficits in a nonhuman primate following MPTP-induced hemiparkinsonism and co-grafting.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Caudate Nucleus; Female; Mac | 1992 |
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-R | 1992 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1992 |
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Disease Mod | 1992 |
Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Behavior, Animal; Carbidopa; Female; Lev | 1992 |
[Tyrosine hydroxylase-immunohistochemical study in the midbrain of experimental MPTP parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Immunohistochemistry; Macaca fascicularis; Me | 1992 |
Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Dopamine | 1992 |
MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine Agents; Electromyo | 1992 |
Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Catecholamines; Dopam | 1992 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1992 |
Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Fluorescent Antibody Technique; Macaca fascic | 1992 |
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1992 |
Molecular basis of discrepancies in neurotoxic properties among 1-methyl-4-aryl-1,2,3,6-tetrahydropyridines.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Dopamine; Dopamine Agents; G | 1992 |
MPTP-induced "parkinsonism" in the goldfish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Brain; | 1992 |
Chronic administration of MPTP to monkeys: behavioural morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Dopamine | 1992 |
Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: the symptomatic versus the asymptomatic condition.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Macaca mula | 1992 |
Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic beta-Antagonists; Animals; Macaca fascicula | 1992 |
Mitochondrial factors involved in Parkinson's disease by MPTP toxicity in Macaca fascicularis and drug effect.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Dihydroergotoxine; Energy Metabo | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; | 1992 |
Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Corpus Striatum; Dopamine; Homova | 1992 |
Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldosterone; Animals; Circadian Rhythm; Disease Models | 1992 |
Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cocaine; Disease Models, Animal; Dopamine; Im | 1992 |
A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Gold | 1992 |
In vivo distribution of catecholamine reuptake sites in human brain gives clues to the physiopathology of MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Catecholamines; Female; Frontal Lobe; Humans; M | 1992 |
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-I | 1992 |
Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Female; Lev | 1992 |
Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain Tissue Transplantation; Caudate Nucleus; Dihydro | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carbo | 1992 |
MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; | 1992 |
Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Behavior, Animal; Carotid Arteries | 1992 |
Lack of major olfactory dysfunction in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Female; Humans; Injections, Intravenous; Male; | 1992 |
Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Par
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1991 |
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Mapping; Callitrichinae; D | 1991 |
Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Functional Lateralit | 1991 |
Fetal nondopaminergic neural implants in parkinsonian primates. Histochemical and behavioral studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Tissue Transplantatio | 1991 |
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Antiparkinson Agents; Bloo | 1991 |
Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Electrophysio | 1991 |
Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Basal Ganglia; Dopamine Agents; | 1991 |
Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Blinking; Locus | 1991 |
Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Macaca fascicularis; Male; O | 1991 |
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Dopamine; Dopamine Agen | 1991 |
Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Dopamine; Female; Globus Pa | 1991 |
Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calbindins; Dopamine; Immunohistochemistry; M | 1991 |
Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Survival; Mice; Mice, Inbred | 1991 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Tremor in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Electromyography; Female; Humans; Male; Parkins | 1992 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Corpus Striatum; Dopamine; Fem | 1991 |
Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformatio | 1991 |
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dominance, Cerebral; Macaca fa | 1991 |
Dopamine and basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric A | 1991 |
Neuronal transplantation in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Ganglia, Sympathetic; Macaca; Nerve | 1991 |
Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dialysi | 1991 |
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzodiazepinones; Cholecyst | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1991 |
The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Corpus Striatum; Dopamine; G | 1991 |
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aged; Aging; Caudate Nucleus; Cell Surviv | 1991 |
Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acoustic Stimulation; Animals; Corpus Striatum; Dopami | 1991 |
Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Enkephalin, Methionine; Female | 1991 |
The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Injections, Intra-Arterial; | 1991 |
Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Clonidine; Disease Models, Animal; | 1991 |
Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Corpus Striatum; Denervation; Dop | 1991 |
Hemiparkinsonism in monkeys following unilateral common carotid artery infusion of MPTP. A study of behavior, biochemistry and histology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Disease Models, Animal; Fem | 1991 |
Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Catecholamines; Corpus Stri | 1991 |
Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Corpus St | 1990 |
The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dopamine; Globus Pallidus; Imm | 1990 |
Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Humans; Mice; Parkins | 1990 |
Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; Injections, | 1990 |
Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callitrichinae; Dopamin | 1990 |
Tissue grafting and immunosuppression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Fetal Tissue Tr | 1991 |
Apparent unilateral visual neglect in MPTP-hemiparkinsonian monkeys is due to delayed initiation of motion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Behavior, Animal; Female; Levodopa | 1991 |
Responses of striatal neurons to peripheral sensory stimulation in symptomatic MPTP-exposed cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Corpus Striatum; Male; Neurons; Parkins | 1991 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1991 |
[Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Fibers; Age Factors; Animals; Corpus Striat | 1990 |
Transplantation of autologous superior cervical ganglion into the brain of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Ganglia, Sympathet | 1990 |
[Adrenal medullary graft induces recovery of the host nigrostriatal dopaminergic system in MPTP-induced mouse model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Chromaffin System; Corpus St | 1990 |
[Spontaneous saccades in MPTP-induced hemi-parkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Macaca; Parkinson Disease, Sec | 1990 |
Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compounds on mitochondrial respiration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Brain; Dose-Response | 1990 |
6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Dihydroxyphenylalanin | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
[Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopa | 1990 |
Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Corpus Striatum; Dop | 1990 |
Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Injections, Intrav | 1990 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Dizocilpine Maleate; Female; Glo | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
MAO-B and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Disease Models, Animal; Huma | 1990 |
[Effects of difenin on experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Male; Motor Cortex; Parkinso | 1990 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Di | 1990 |
[Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Female; I | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Str | 1990 |
Attenuation of the early anterior negativity of median nerve somatosensory evoked potential in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electric Stimulation; Evoked Potentials, Soma | 1990 |
Autologous transplantation of the superior cervical ganglion into the brain of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Ganglia, Sympathetic | 1990 |
The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Caudate Nucleus; Female; Fet | 1990 |
Cognitive change following MPTP exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Cognition; Humans; Neuropsychological Tests; Pa | 1990 |
Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Fe | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1990 |
Role of interaction of the tanycytes of the third ventricle of the brain with the vascular bed endothelium in enzymatic activation of the parkinsonism-inducing proneurotoxin MPTP in rat brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Cerebral Ventricles; Endot | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Callitrichinae; Cholecystoki | 1986 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Corpus Striatum; Male; Mice; | 1987 |
[Effects of substance P on experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Extrapyramidal Tracts; Male; | 1989 |
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Brain; Callitrichinae; Corpus Striatum | 1989 |
Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1989 |
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 1989 |
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; B | 1989 |
Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Female; Macaca fascicularis; | 1989 |
GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; G(M1) Ganglioside; | 1989 |
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Ag | 1989 |
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Topical; Animals; Callitrichinae; Dopa | 1989 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; D | 1989 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
A sheep model for MPTP induced Parkinson-like symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 1989 |
Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Chromatography, | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, | 1989 |
MPTP-induced Parkinson-like disease in sheep: clinical and pathologic findings.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Female; Infusions, In | 1989 |
Chemically induced Parkinson's disease. II: Intermediates in the oxidation and reduction reactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium ion and its deprotonated form.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electrons; Humans; Indicators and Reagents; K | 1989 |
[Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caudate Nucleus; | 1989 |
Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agen | 1989 |
Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on ultrastructure of nigral neuromelanin in Macaca fascicularis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytoplasmic Granules; Female; Macaca fascicul | 1989 |
Mitochondria covered with a net of parallel and latticed filaments in nigral neurons of monkeys with experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Macaca; Macaca fascicularis; Microscopy, Elec | 1989 |
Transplantation advances in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cerebellum; Chlorocebus aeth | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug | 1989 |
Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; DNA; Dopamine; Enkephalins; | 1989 |
[Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electroencephalography; Hippocampus; Oxotremo | 1989 |
[The role of the system of reverse capture of dopamine in the development of experimental Parkinsonism under the effect of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and its pyridine analogs].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain; Chemical Phenomena; C | 1989 |
Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Disability Evaluation; Humans; Injections, Intr | 1989 |
Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Brain; Brain Chemistry; Female | 1988 |
Production in nature of compound resembling methylphenyltetrahydropyridine, a possible cause of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Chemical Phenomena; Chemistry; Humans; Parkinson Disea | 1985 |
Budipine and the MPTP binding site.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; H | 1985 |
Parkinsonism as late toxic effect of dihydropyridines?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease, Secondary; Pyridines; Pyrid | 1986 |
Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Disease Models, Animal; | 1986 |
Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Brain Mapping; Corpu | 1986 |
Free radicals, lipid peroxidation, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radicals; Humans; Lipid Peroxides; Parkinson Dise | 1987 |
MPTP, selegiline, and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease, Secondary; Phenethylamines; | 1987 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fasc | 1987 |
Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Humans; Lisuride; Mac | 1987 |
Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Corpus Striatum; Dopamine; | 1987 |
MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Brain | 1987 |
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 1987 |
Skin colour, MPTP, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Female; Humans; Male; Melanins; Parkinson Disease, Sec | 1987 |
Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Dopamine; Macaca fascicularis; | 1987 |
An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Cell Count; Disease Models, A | 1987 |
Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain; Cats; Dopamine; Glial Fibr | 1988 |
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Dopamine Ag | 1987 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; | 1988 |
Transplant improves hemiparkinsonian syndrome in nonhuman primate: intracerebral injection, rotometry, tyrosine hydroxylase immunohistochemistry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Immunohistochemistry; Injections; Maca | 1988 |
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Carotid Arteries; Corpus Str | 1986 |
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Callitrichinae; Dopamine Antago | 1988 |
Saccadic eye movement deficits in the MPTP monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Eye Movements; gamma- | 1986 |
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Inclusion Bodies; Locus Coerul | 1986 |
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Culture Techniques; Dopamine; Humans; | 1987 |
Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Caudate Nucleus; Chromaffin | 1987 |
N-methyl-4-phenylpyridine (MMP+) together with 6-hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calcium; Carbony | 1986 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Huma | 1986 |
The MPTP story: an introduction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1986 |
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Arylsulfotransferase; Blood Platelets; Humans; Monoami | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Pathology of MPTP in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Callitrichinae; Catecholamines; Dose-R | 1987 |
Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Maca | 1987 |
Parkinson's disease: current view.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Monoamine Oxidase; Monoamine O | 1987 |
Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease M | 1987 |
Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Cerebral Cor | 1988 |
Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Callitrichinae; Choline O-Acetyltransf | 1986 |
Mechanisms of recovery in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Corpus Striatum; Parkinson Di | 1988 |
Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Corpus Striatum; Dopamine; Fe | 1988 |
Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Macaca mulatta; Male; | 1988 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, | 1985 |
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
MPTP in mice: treatment, distribution and possible source of contamination.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Environmental Exposur | 1988 |
Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Eye Movements; Female; Glucose; Levodo | 1988 |
Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Mice; Mice, Inbred C57BL; Mi | 1988 |
Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1988 |
Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Clomipramine; | 1988 |
[Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Male; Parkinson Disease, Secondary; Pyridines | 1988 |
Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Nucleus; Golgi Apparatus; Locus Coeruleu | 1988 |
Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Corpus Striatum; Dopa | 1988 |
Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electroretinography; Evoked Potentials, Visua | 1988 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Macaca fascicular | 1988 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Chemical Phenomena; Chemistry; Chromatography, | 1988 |
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic | 1988 |
The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ergolines; Female; Li | 1988 |
Effect of MPTP-induced parkinsonism in monkeys on the urinary excretion of HVA and MHPG during debrisoquin administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatinine; Debrisoquin; Female; Glycols; Hom | 1988 |
Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatograph | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Homovanillic Acid; H | 1988 |
Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Functional Lateral | 1988 |
Cerebral metabolism of parkinsonian primates 21 days after MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Corpus Striatum; Dopa | 1988 |
Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Chromatography, High P | 1988 |
Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Functional Laterality; Macac | 1988 |
A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Equ | 1988 |
Recovery of dopaminergic fibers in striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse is enhanced by grafts of adrenal medulla.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Corpus Striatum; Dopamine; M | 1988 |
Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Dopamine; Fetus; | 1988 |
Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology, and biochemistry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Cats; Dopamine; Dose | 1986 |
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Deoxy Sugars; Deoxyglucose; Di | 1986 |
Toxin-induced parkinsonism: recent developments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Illicit Drugs; Male; Parkinson Disease; Parkin | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Female; Hypothalamic Diseases; Hy | 1986 |
Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Brain Che | 1986 |
Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atrophy; Brain; Disease Models, Animal; Femal | 1986 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidop | 1986 |
The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1986 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; | 1986 |
Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Emotions; Eye Moveme | 1986 |
MPTP toxicity: clinical features.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Bromocriptine; California; Chemical Industry; District | 1986 |
MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Parkinson Disease, | 1986 |
MPTP: a pharmacological tool to study parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Monoamine Oxidase Inhibitors; Parkins | 1986 |
[Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Parkinson Disea | 1986 |
[Parkinsonism and MPTP (methylphenyltetrahydropyridine)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease, Secondary; Pyridin | 1986 |
"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromine; Corpus Striatum; Disease Models, Ani | 1986 |
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1986 |
[Treatment of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Drug Therapy, Combination | 1986 |
Saccade responses to dopamine in human MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Blepharospasm; Brain Mapping; Dopamine; Eye Movements; | 1986 |
Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adult; Animals; Brain; Do | 1987 |
Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Blood Glucose; Deoxyglucose; | 1987 |
Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1987 |
Development of new pharmacological approaches in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cysteinyldopa; Delayed- | 1987 |
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; | 1986 |
Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Deoxyglucose; Disease | 1987 |
Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenyl-pyridinium ion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Electrons; Humans; Kineti | 1987 |
Symposium on a Long Time Clinical Care of Parkinson's Disease. Tokyo, April 12, 1986. Proceedings.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Parkinson Disease, | 1987 |
Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Disease Models, Animal; Humans; Parkin | 1987 |
Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformatio | 1987 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1987 |
Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Dopamine; Fetus; | 1987 |
Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Fetus; Levodopa; Macaca mulatta; Me | 1987 |
Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Glucose; Levodopa; Macaca mula | 1987 |
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Humans; Male; Parkinson Disease, Secondary; Pyr | 1987 |
Behavioral and biochemical studies in monkeys made hemiparkinsonian by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carotid Arteries; Cerebral Cortex; Corpus Str | 1987 |
The use of the MPTP-treated mouse as an animal model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Corpus Striatum; Disease Mod | 1985 |
New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain Chemistry; | 1985 |
Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Dopamine; In Vitro Te | 1985 |
MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electromyography; Mac | 1985 |
Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Deoxy Sugars; Deoxygl | 1985 |
Spinal cord metabolism of the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diencephalon; Dopamine; Glucose; Macaca fasci | 1985 |
Intellectual changes in patients with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Attention; Depression; Humans; Intelligence; Pa | 1985 |
Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adrenal Medulla; Animals; | 1985 |
The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Corpus Striatum; Dopamine; Humans; Middle | 1985 |
MPTP and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Biomechanical Phenomena; Humans; Nervous System | 1985 |
Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Bromocripti | 1985 |
1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cytochrome Reduc | 1985 |
Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cerebral Cortex; Corpus Striatum; Deox | 1985 |
Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Catecholamines; Female; Locu | 1985 |
A simple quantitative bradykinesia test in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopa | 1985 |
Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Fetus; Macaca mulatta; Mesencephalon; Parkins | 1985 |
Parkinson's disease: an environmental cause?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Haplorhini; Humans; Mice; Parkinson Disease; | 1985 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Glands; Animals; Biogenic Amines; Brain; Brain | 1985 |